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ABSTRACT
PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA): 
IMMUNOASSAY DEVELOPMENT AND 
CHARACTERIZATION OF TRANSCRIPTIONAL REGULATION
Zhen Xiao
Eastern Virginia Medical School and Old Dominion University, 2002 
Director: Dr. George L. Wright, Jr.
Prostate cancer (PCA) is the most common cancer and the second leading cause 
o f death among American men. The high mortality is greatly attributed to the lack of 
early detection tools and effective treatment for metastasis and relapses. Biomarkers that 
can discriminate benign from malignant tumor and signal the development o f androgen 
independent and metastatic tumor are needed. A biomarker designated prostate specific 
membrane antigen (PSMA) has the potential to fulfill this need. The objective of this 
study is to develop a clinically useful immunoassay for quantitation o f serum PSMA and 
to study the molecular mechanism underlying the upregulation o f  the PSMA gene after 
androgen deprivation therapy. Surface Enhanced Laser Ionization/Desorption (SELDI) 
ProteinChip* mass spectrometry was used for the first aim. A baculovirus recombinant 
PSMA was generated, purified and characterized. After the SELDI immunoassay 
conditions were optimized, a standard curve was established using rPSMA as the 
substitute antigen. Serum PSMA levels, as measured by SELDI immunoassay, were able 
to distinguish benign from malignant prostate disease. To understand the transcriptional 
regulation o f the PSMA gene, the second aim focused on the 14 AP-1 sites in the 5' 
region of the PSMA gene. By Northern blot, the PSMA mRNA levels in LNCaP cells 
were found to be increased by the inducers o f A P-l, EGF and TP A, and decreased by
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
androgens. The PSMA promoter activity, as analyzed by luciferase assay, was also 
induced by EGF and cotransfected AP-1 proteins, but suppressed by androgens. The 
binding o f AP-1 to three putative AP-1 sites in the vicinity o f the PSMA transcription 
initiation sites was demonstrated by gel shift assay. The DNA binding was also decreased 
by androgens and increased by EGF. Gel shift competition further indicated that the AP-1 
binding might be inhibited by the interaction between androgen receptors and AP-1. To 
summarize this study, the serum PSMA level was measured by SELDI immunoassay and 
was shown to be a more effective biomarker than PSA for differentiating benign from 
malignant prostate disease. Moreover, PSMA gene transcription is activated by AP-1 and 
suppressed by androgens possibly through the inhibition o f AP-1 binding to the PSMA 
promoter by androgen receptor.
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A. REVIEW OF THE LITERATURE
1. Prostate Cancer and PSA Test
Prostate cancer (PCA) is the most common cancer in men in the United States with 
198,100 new cases estimated to be diagnosed in 2001. PCA is second to lung cancer in 
the number o f cancer deaths in men with 31,500 deaths estimated for 2001(1). The 
high mortality rate is due mainly to the difficulty in detection and treatment o f patients 
with the aggressive, lethal form of PCA. According to the Surveillance. Epidemiology, 
and End Results (SEER) Program of the National Cancer Institute, one-third o f 
patients who are diagnosed with PCA have already developed advanced malignancy 
(2,3). These patients might receive palliative treatments and eventually die with PCA. 
On the other hand, for those patients who have been diagnosed with early stage 
localized PCA. more treatment options are available, including radical prostatectomy, 
radiation therapy, and recently developed cryotherapy. Patients who fail these 
treatment strategies, or are diagnosed with extraprostatic spread, will receive systemic 
androgen deprivation therapy. However, androgen independent tumor and/or 
metastatic disease are very likely to prevail in these patients, pointing to the need for 
alternative therapies to effectively treat hormone refractory disease.
The introduction o f the PSA test has greatly enhanced the screening and early
The model o f this dissertation is Cancer Research.
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detection of PCA (4). The shortcoming of the PSA test is its lack o f sensitivity in 
discriminating PCA from benign prostate hyperplasia (BPH), especially in the PSA 
range of 4-10ng/ml. which is also called the 'grey zone’ (Fig. 1) (5,6). The addition of 
the PSA-related parameters such as PSA velocity, density and free to total PSA ratios 
has slightly improved the specificity, reducing the number o f unnecessary biopsies (4). 
While PSA has remained the best and most widely used tumor marker, additional 
biomarkers are still required to improve the early detection, diagnosis and prognosis of 
PCA (7-10). It is in this context that the discovery and clinical potential o f prostate 
specific membrane antigen (PSMA) have been viewed to be very meaningful and 
promising.
2. Discovery of PSMA
PSMA was first identified by a murine monoclonal antibody produced against 
LNCaP cell membranes and designated 7E11-C5.3 (7E11) (11). The discovery process 
is summarized in Fig. 2. Tryptic peptide sequences o f the 7E11 immunoprecipitated 
protein were analyzed and used to design degenerate primers, resulting in the cloning 
o f a 2.65kb PSMA cDNA by RT-PCR (Genebank Accession #M99487) (12). SDS- 
PAGE and Western blotting analyses revealed PSMA to be a lOOkDa glycoprotein 
with the ability to form dimers o f 180-200kDa (13,14).
3. Biological Characteristics of PSMA
PSMA cDNA sequence analysis showed that PSMA is a 750 amino acid type II 
transmembrane glycoprotein (Fig. 3). It is composed o f three structural domains, with








 P C A ----------------A.I. / m etastasis
Fig. 1. A schematic representation o f the change of serum PSA levels 
during prostate cancer progression. X  axis, the progression o f  prostate 
cancer from normal to benign prostate hyperplasia (BPH), prostate 
cancer (PCA), and eventually androgen independent (A.I.) and 
metastatic tumors. Y axis, serum PSA level in ng/ml. The serum PSA 
levels are low in normal men (<4ng/ml). When PSA levels fall in the 
range o f  4 to lOng/ml, it becomes difficult to discriminate BPH and 
PCA. The grey shaded area represents the overlap between BPH and 
PCA. After the treatment such as surgical removal o f prostate, 
radiation therapy or androgen deprivation therapy. PSA levels might 
decline while the tumors continue to progress. In this situation, 
surrogate tumor biomarkers are needed for post treatment prognosis.
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PSMA cDNA *------  Screening of LNCaP cDNA library •«—  probe
Fig. 2. The discovery process o f PSMA protein and gene.
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Intracellular (19aa)
7E11 epitope NH2
Fig. 3. PSMA is a transmembrane glycoprotein located on the cell membrane 
TM, transmembrane domain o f PSMA. The epitope for MoAb 7E11 is at the 
19 amino acids at the intracellular domain. An alternatively spliced mRNA 
results in PSMA', a protein without the membrane-spanning and intracellular 
regions.
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a 19 amino acid N-terminal intracellular domain, followed by a 24 amino acid 
transmembrane domain and a 707 amino acid extracellular domain (12). The epitope 
recognized by 7E11 is located intracellularly at the N-terminal 19 amino acids (15). 
Glycosylation analysis indicated that there are 10 N-linked glycosylation sites and 
little O-linked glycosylation. Carbohydrate constitutes about 25% of the total 
molecular weight (16).
Extensive immunohistochemical studies using 7E11 demonstrated that PSMA was 
expressed predominantly in normal, benign and malignant prostate epithelia. with 
weak reactivity in the small intestine, brain, kidney and salivary glands (14.17-19). 
Recently, researchers have developed a number o f second generation antibodies that 
revealed PSMA reactivity in a variety o f solid tumor-associated neovasculatures but 
not normal vasculature (20.21). PSMA appeared to be down regulated in benign 
prostatic hyperplasia (BPH) and overexpressed in poorly differentiated primary 
tumors. The highest expression o f PSMA was found in bone and lymph node 
metastatic prostate carcinomas, especially in patients with recurrences after androgen 
deprivation therapy (19. 22-24). Besides the observations at the protein level, a similar 
expression profile was observed at mRNA level. In needle biopsy specimens using in 
situ hybridization with a PSMA specific RNA probe. PSMA transcripts were shown to 
be limited to the basal cells in the normal prostate glands, whereas they were detected 
at a much higher level in carcinoma cells from hormone-refractory patients than in the 
cells o f those who showed a good response to hormonal therapy (25). The effect of 
androgen on PSMA level was further studied in vitro using LNCaP as the model. By 
ELISA, PSMA expression was shown to be upregulated when cells were grown in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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androgen stripped medium, and decreased in cells grown in androgen supplemented 
medium (23). Another study using RNase protection assay also showed the 
downregulation o f PSMA RNA by androgens (13). These results clearly indicate that 
the expression o f PSMA, at either protein or RNA level, is closely associated with 
malignant transformation and development o f hormone independence. Besides being 
expressed in prostate and other tissues, PSMA was also detected in body fluids. 
Western blotting showed the presence of PSMA in both serum and seminal plasma 
(14.26.27). In serum, the highest level o f PSMA was found in patients with late-stage 
prostate cancer (14.27).
Type II transmembrane proteins are usually proteases, receptors or transport 
proteins, but the function o f PSMA is not clear. Nonetheless, there are a number of 
speculations. A human brain enzyme called N-acetylated a-linked acidic dipeptidase 
(NAALADase) showed 86% homology to a region of PSMA (28). NAALADase 
cleaves a-linked glutamate from the N-acetylaspartylgiutamate (NAAG). and NAAG 
is a potential neurotransmitter in brain. Another enzymatic activity that might relate to 
PSMA is folate hydrolase (FOLH). which removes the y-linked glutamates from folate 
in a sequential manner. The FOLH in human duodenal intestine shares high sequence 
homology with PSMA (29). Folate has been known to be important for prostate tissue 
development. While in vitro enzymatic studies demonstrated both NAALADase and 
FOLH activities in PSMA-expressing LNCaP cells, the in vivo functional implication, 
particularly in prostate tissue warrants further investigation.
Based on the cloned cDNA. the entire gene for PSMA has been isolated and 
sequenced (Genebank accession #AF007544) (30). The gene is composed of 19 exons
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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spanning about 62kb o f genomic DNA on the short arm o f chromosome 11 (11 pi 1.2) 
(31). Fluorescent in situ hybridization (FISH) analysis suggested the potential 
presence of a second related gene on the long arm o f chromosome II (1 lq  14). but the 
relevance o f this second gene to PSMA and to prostate cancer development is not 
clear (32). Since androgen has shown the ability to change the PSMA RNA level, the 
PSMA promoter region was recently cloned in an attempt to study the androgen 
responsiveness at the transcription level (30.33). However, the data on promoter 
activity were ambiguous in those studies, probably due to the difficulty in transfection 
of LNCaP cells. Therefore, the molecular mechanism by which androgen alters the 
PSMA RNA level remains unknown.
4. Clinical Application o f PSMA
Since its initial discovery. PSMA has received attention as a potential biomarker 
for detection/diagnosis, prognosis, and as a therapeutic target. The orientation of 
PSMA on prostate cell membranes makes it an attractive target for imaging, 
radiotherapy, and immunotherapy. Anti-PSMA MoAb 7 E I 1 conjugated with 11‘in and 
marketed by Cytogen Corporation as Prostasint*. is being used for radiographic 
imaging, and shows to provide higher sensitivity than computed tomography (CT) 
scanning for detecting lymph node metastatic prostate cancer and disease outside the 
field o f surgical exploration (34-36). 90Y conjugated 7E11 has recently entered phase 
III trials for radiation therapy of prostate cancer recurrence and metastasis (37.38). 
Second generation antibodies that recognize the extracellular domains of PSMA. are 
in clinical trials to evaluate their utility for radiological imaging and radiotherapy
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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(39,40). The potential o f these antibodies to develop anti-angiogenic therapies has also 
been suggested (41).
Since PSMA is highly specific for prostate epithelial cells and its expression is 
elevated with PCA progression, it was proposed as an ideal antigen to stimulate 
immune responses against prostate cancer cells. Following this consideration, 
researchers have pulsed autologous dendritic cells (DCs) with PSMA derived peptides 
and infused DCs into patients with metastatic hormone refractory prostate cancer, in 
an attempt to stimulate cytotoxic T cell killing of tumor cells (42). This approach is 
currently in phase II clinical trials and has provided some promising immune 
responses in patients with post-radical recurrences (43-47).
PSMA has also been used for molecular staging and diagnostic approaches. Nested 
RT-PCR using PSMA specific primers has detected hematogenous circulating 
prostatic cells, which showed a much higher sensitivity than the PSA-based assay (48- 
5 1). Although the finding of prostatic cells in the circulation does not necessarily 
imply distant metastasis, the results have presented a step forward in applying PSMA 
for early detection o f aggressive PCA. and thereby offering the patients more options 
for treatments in a likely curable stage. This method is currently subject to further 
modification in order to improve the accuracy and reproducibility.
PSMA has been detected in serum by Western blotting, with high levels correlated 
with higher pathological stages and worse prognostic outcome (14.27). The inverse 
correlation o f PSMA with androgen levels is o f particular interest, making PSMA a 
valuable surrogate biomarker for PCA progression, especially in instances when the 
expression o f PSA is decreased after surgical or hormone ablation. Considerable
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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efforts have been devoted to the development o f a quantitative immunoassay for 
measuring PSMA in body fluids. Various combinations o f  antibodies to both the 
intracellular and extracellular domains have been used in ELISA formats in an attempt 
to quantitate PSMA. However, the progress has fallen behind the anticipation because 
a good pair of ‘capture' and ‘detector’ antibodies has not been identified. So far the 
only effective method to detect serum PSMA is still by Western blotting, which is 
useful as a semi-quantitative analytic method for research, but unsuitable as a clinical 
assay.
B. FOCUS OF THE PRESENT INVESTIGATION
PSMA is a potential biomarker for improving the diagnosis and prognosis of 
prostate cancer. It is also an ideal target for gene and immunotherapy strategies. 
However, the clinical application of PSMA remains impeded by two important 
questions:
1) Can serum PSMA levels be quantitated and used as a diagnostic biomarker?
2) How is PSMA regulated by androgens?
Answers to both questions will certainly benefit the basic biology and the clinical 
utility o f PSMA.
Several lines of evidence suggested that PSMA is differentially expressed in BPH 
and PCA (23-25.27). Therefore. PSMA might be useful as a marker, either alone or in 
concert with PSA, to differentiate PCA from BPH in the PSA 4.0ng/ml to lOng/ml 
grey zone; thus reducing the number of unnecessary biopsies. However, in order to
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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critically evaluate PSMA as a biomarker, it is necessary to develop an assay format to 
quantitatively measure PSMA in body fluids. Although Western blot analysis has been 
used to detect PSMA in body fluids, our laboratory and others have found it unreliable 
for quantitation and unsuitable as a clinical assay (14,27.52-55). Attempts to develop 
an immunoassay for quantitation o f PSMA have been unsuccessful due to the lack of 
purified PSMA protein standard and a sensitive method for quantitation. To the best of 
our knowledge, no test is available for measuring PSMA in sera. The clinical 
application necessitates the development of a simple, fast, accurate and reproducible 
approach that can detect and quantitate serum PSMA. Surface Enhanced Laser 
Ionization/Desorption (SELDl) ProteinChip^ technology, an innovative chip based 
affinity mass spectrometry' system was applied to address this question. The 
ProteinChip® system provides a platform for immunoassay development, with the 
capability for immobilizing antibody, which in turn can capture PSMA from serum 
and convert it to a mass signal that correlates to the quantity o f the antigen present.
Besides the lack o f an appropriate tool for quantitation, the clinical application of 
PSMA has also been hampered by the lack of understanding about its gene regulation. 
Although initial observation suggests that the activity of PSMA gene promoter is 
downregulated by androgens and upregulated in the absence o f androgens 
(13,22.23.30,33), no androgen responsive element has been identified. This also 
implies the existence o f other transcriptional enhancer regions that might selectively 
activate the PSMA gene in the absence o f androgens. Therefore the objective o f the 
second part o f this study was to search for such promoter/enhancer regions and related
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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transcription factors to better understand the mechanism o f the PSMA gene regulation 
by androgens.
C. PRELIMINARY STUDY: SEQUENCE ANALYSIS OF THE 5’ REGION OF 
THE PSMA GENE
Based on the hypothesis that transcription factors other than androgen receptors are 
likely to be involved in the regulation of the PSMA gene, a preliminary sequence 
analysis was conducted to search for the possible binding sites for some of the known 
transcription factors, especially those that might be related to the androgen 
responsiveness.
The computer software MacVector was used to analyze a 5.1 kb fragment starting 
from the 5' end o f the PSMA genomic sequence (nts 1-5100). This includes the 2.4kb 
upstream region, the first exon and the first intron o f the PSMA gene. No androgen 
responsive elements were identified in the entire region based on the consensus 
androgen responsive element (ARE) sequence. Instead, a total o f 14 putative binding 
sites for the transcription factor AP-1 family members (c-Jun/c-Fos) were identified. 
Fig. 4A illustrates the physical distribution of the putative AP-1 binding sites 
throughout the 5’ end region (nts 588-4973) of the PSMA gene. Table 1 summarizes 
the features o f these AP-1 sites. For all these 14 AP-1 sites, at least 6 out o f the 7 base 
pairs were matched with the sequence of the consensus AP-1 site.
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13
A.
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PSMA 5 ’ nts 588-4973 AP-1 sites
B. c





Intron 1 ( fl fl ~~J~ LUC I/Pl
pGL2 luciferase vector driven by PSMA promoter and intron I
Fig. 4. AP-1 sites in the 5’ region o f the PSMA gene and the luciferase constructs 
used in this study. A, The distribution o f putative AP-1 binding sites in the 5’ end 
region (nts 588-4973) o f PSMA. The numbers in parentheses stand for the 
beginning and the end nucleotides o f the PSMA fragments in pGL2 constructs PI, 
P2 and I/P 1 according to their position in PSMA genomic sequence (Genbank 
accession number AF007544). B. pGL2 luciferase constructs used in this study.
The PSMA fragments PI, P2 and I/Pl were cloned into the pGL2-basic vector. I/Pl 
is a fragment with Intron 1 added to the 5' end o f PI. The shaded ovals represent 
the putative AP-1 binding sites. The arrows stand for the transcription initiation site 
(nt 2488) o f the PSMA gene.
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Table 1 Putative transcription factor AP-I binding sites present in the PSMA





Number of bp 
matched with the 
consensus sequence
1 649 - TTAtTCA 6 / 7
2 877 - gGAGTCA 6 / 7
3 1 00 8 - TaAGTCA 6 / 7
4 1 0 9 3 - TTAaTCA 6 / 7
5 1 1 4 5 + TTAGTCA 7 / 7
6 1 2 9 9 - TTtGTCA 6 / 7
7 1 5 0 9 + TGgGTCA 6 / 7
8 19 6 4 + TGcCTCA 6 / 7
9 2 3 2 1 + TTAtTCA 6 / 7
10 2 3 7 0 - TTAtTCA 6 / 7
11 3 8 9 9 - TGtGTCA 6 / 7
12 4 2 1 7 - TTAGTCc 6 / 7
13 4 5 9 3 + TGAGTCA 7 / 7
14 4 8 2 6 - aGAGTCA 6 / 7
C onsensus A P -1 binding site
TTAGTCA
TGAG/CTCA
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The result from this sequence analysis brought the AP-1 transcription factor family 
to our attention, because the members o f this family interact with androgen receptors 
and the interactions have mutual effect on both o f their transactivation ability (56.57). 
In order to determine if AP-1 is involved in the androgenic regulation of the PSMA 
gene, the following specific aims were proposed: 1) To determine if  the AP-1 inducers 
such as EGF and TPA can increase the expression of PSMA; 2) To analyze the effect 
of AP-1 family members on the PSMA promoter activity; and 3) To analyze the DNA 
binding activity o f AP-1 proteins in the PSMA promoter region and the effect of 
androgens on the AP-1 DNA binding. The results from this part o f the study would 
reveal the mechanism underlying the androgenic regulation o f the PSMA gene 
expression.





1. Cell and Cell Culture
Sf9 cells derived from Spodoptera frugiperda ovarian cells and High Five® (Hi5) 
cells derived from Trichoplusia ni egg cell homogenates were obtained from 
Invitrogen (Carlsbad. CA). Both insect cell lines were grown at 27°C. either as 
monolayers or as suspension cultures in spinner flasks in Hink's TNM-FH medium 
(Grace's medium) supplemented with 10% fetal bovine serum (FBS) and 1% 
antibiotic-antimycotic solution (Sigma. St. Louis. MO). For recombinant PSMA 
expression, viral infections were performed on Hi5 cell monolayers grown in Excel 
405 serum free medium (JRH Biosciences. Lenexa. KS).
LNCaP and PC-3 cell lines were obtained from the American Type Culture 
Collection. LNCaP cells were maintained in RPMI 1640 medium supplemented with 
5% Fetal Bovine Serum (FBS). Cells between the 29th and 42nd generation were used 
in these experiments. PC-3 cells were maintained in RPMI 1640 medium 
supplemented with 10% FBS. Cells o f the 18th to the 20,h generation were used in the 
experiments.
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2. Bacterial Strains and Plasmids
The pBlueScript SK (Stratagene, La Jolla, CA) and pGEMT plamids (Promega. 
Madison, WI) were amplified in JM109 E. Coli strain. The baculovirus transfer vector 
pBlueBacHisB (Invitrogen, Carlsbad, CA) was amplified in Top 10 E. Coli strain.
3. Antibodies
Anti Xpress antibody was purchased from Invitrogen (Carlsbad. CA). Anti-PSMA 
MoAb 7E11-C5 (IgGl) was purified from the cell culture medium of ATCC 
hybridoma line HB-10494 using Affi-Gel® Protein A MAPS® II kit (Bio-Rad. 
Hercules. CA). The following rabbit polyclonal antibodies were obtained from Santa 
Cruz Biotechnology (Santa Cruz. CA): anti c-Jun (N) (sc-45x). anti c-Fos (4) (sc-52.\). 
and anti AR (N-20) (sc-816x).
4. Patients and Serum Samples
The serum samples used in this study were obtained from the serum bank o f the 
Virginia Prostate Center at Eastern Virginia Medical School, and were the same group 
of samples that had been used previously to analyze the serum levels o f PSMA by 
Western blotting (27). All sera were collected from consented patients following the 
study protocol approved by the Institutional Review Board. The normal male 
population was defined by a negative DRE and a PSA <4.0ng/ml. The age range for 
normal males under age 50 was 27-39 (mean o f  33.9). and 54-71 (mean o f 60.3) for 
normal males over 50. Pre-treatment serum samples from patients with benign or
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malignant prostate disease were used in this study. Benign prostate hyperplasia (BPH) 
patients were those who had bladder outlet obstructive symptoms, increased PSA 
levels (>4ng/ml), and confirmed to be BPH upon transrectal ultrasound biopsy. The 
prostatitis population consisted o f patients with chronic symptom complex attributed 
to prostatic source and absent o f infection by urine analyses and culture at the time of 
sample collection. Prostate cancer patients included clinical stages (T1 to T3).
B. METHODS
1. Construction of pBlueBacHis-PSMA Baculovirus Transfer Vector
Firstly, the 2.65kb full-length PSMA cDNA (GenBank accession number M99487) 
was amplified by RT-PCR using messenger RNA isolated from LNCaP cells as 
template, and cloned into pBlueScript SK vector. The insert was verified by sequence 
analysis. To generate a recombinant PSMA baculovirus transfer vector, primers were 
designed to add BamHI and Hindlll restriction sites to 5' and 3' ends o f pBlueScript- 
PSMA respectively by PCR (5 'AGGATCCGATGTGGAATCTCCTT: 3* 
AAAGCTTCCCTCGAGTTTTTTTTT). The amplified product was cloned into 
pGEMT vector, restricted with BamHI/Hindlll. and inserted into the pBlueBacHisB 
vector. The PSMA insert in pBlueBacHisB construct was verified by sequencing.
2. Generation of Recombinant His-tagged PSMA Baculovirus
Cotransfection o f Sf9 cells with wild-type baculovirus DNA and the transfer vector 
was performed using the Bac-N-Blue Transfection Kit from Invitrogen. A
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recombinant baculovirus was identified as blue and occlusion body negative (occ-) 
plaques by plaque assays on medium containing x-gal. The recombinant baculovirus 
was purified by four rounds o f plaque assay. Insertion o f the PSMA gene into the viral 
genome was verified by PCR using primers flanking the polyhedrin gene (forward: 
TTT ACT GTTTT CGT A AC AGTTTT G; reverse: C A AC A AC GC AC AG A AT CT AGC).
3. Expression of Recombinant His-tagged PSMA
A high-titer viral stock (>108 pfu/ml) was generated from the initial infection and 
used for large-scale rPSMA expression. Hi5 cell monolayer cultures were infected and 
a time course study was performed with different multiplicities of infection (MOI). 
Both cell pellets and culture supernatants were harvested at different time points and 
analyzed by Western blotting to determine the cellular localization o f recombinant 
protein. After optimizing the rPSMA expression, a large-scale infection was 
performed in Hi5 cells and the infected cells were harvested at the expression peak for 
rPSMA. Cell pellets were stored at -80°C for further purification.
4. Purification o f Recombinant His-tagged PSMA
Whole cell lysates were prepared by solubilizing the cell pellets in lysis buffer 
consisting of 50mM Tris.HCl pH8.0, 500mM NaCl. 0.5% SDS. 1% Igepal (Sigma. St. 
Louis. MO) and the protease inhibitor cocktail (lOpg/ml Leupeptin. lOpg/ml 
Aprotinin, ImM PEFAbloc. lOpg/ml Pepstatin A). The lysates were subjected to 
sonication at 200watts for 20sec x3 pulses with 20sec cooling intervals in between 
pulses. Following a DNase I (lOOpg/ml) digestion at room temperature for 30min.
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lysates were centrifuged at 14,000rpm for 20min. The clarified supernatant was used 
as the starting material for rPSMA purification.
The Talon Metal Affinity Resin (Clontech, Palo Alto. CA) was used for protein 
purification. The insect cell lysate supernatant was added to the Talon Resin pre­
equilibrated in lysis buffer. The mixture was agitated at room temperature for 1 hr. then 
transferred onto a gravity column, which was washed with 10 bed volumes o f lysis 
buffer (pH8.0). The rPSMA was eluted by adding 4 bed volumes each o f  the lysis 
buffer containing increasing concentrations o f imidizole (lOmM, 50mM. lOOmM and 
200mM). The flow-through and 0.5ml eluted fractions were collected and subjected to 
Western blot analysis. The PSMA containing fractions were pooled, dialyzed against 
lysis buffer, and concentrated using Centricon concentrators (MWCO 50kD. Amicon. 
Beverly. MA). The purified rPSMA protein was quantitated by the BCA protein assay 
(Pierce Chemical. Rockford. IL), and stored at -20°C until used.
S. Gel Electrophoresis and Western Blot Analysis
Sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
Western blot analyses were performed as previously described (58). Briefly, protein 
samples were electrophoresed on 10% SDS-PAGE and visualized by silver staining. 
For Western blotting, the gels were blotted onto Immobilion-P membranes (Millipore. 
Bedford, MA). The membranes were blocked with 1% I-block (Tropix. Bedford. MA) 
in PBS buffer, incubated with primary antibody, washed 3x with TBST (1 OOmM 
Tris.HCl pH7.5, 150mM NaCl, 0.1%Tween-20) and then incubated with horseradish 
peroxidase-conjugated goat anti-mouse IgG antibody (Sigma, St. Louis, MO). Finally
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the membranes were washed 3x with TBST. lx with TBS, and the protein bands were 
visualized by ECL according to manufacturer's instructions (Amersham. Arlington 
Heights. IL).
6. Mass Spectrometry
In addition to gel electrophoresis and Western blotting, the purity o f rPSMA was 
also determined on the ProteinChip® using Surface Enhanced Laser 
Desorption/Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS) 
(Ciphergen Biosystems, Inc.. Palo Alto. CA) (59). Purified recombinant PSMA end 
product was applied directly on a Ni^-coated Immobilized Metal Affinity (IMAC) 
ProteinChip®. The chip was washed with HjO briefly for 5 seconds, and sinapinic acid 
(Sigma. St. Louis. MO) was added as the energy absorbing molecule. The chip was 
then placed in the PBS-1 SELDI mass reader, and the mass spectra were collected 
with a laser intensity o f 60.
7. Glycosylation Analysis
Prior to enzymatic digestions, each exoglycosidase was tested to make sure it was 
enzymatically active and met the manufacture's specifications. Briefly. o-Nitrophenyl 
P-D-galactopyranoside and p-Nitrophenyl N-acetyl-P-D-glucosaminide (Sigma) were 
used as the substrates for p-galactosidase and P-N-acetylhexosaminidase, respectively. 
The production of O-Nitrophenol and p-Nitrophenol was monitored spectrometrically 
using wavelengths o f 410nm and 330nm. respectively. The increases in absorbance 
indicated the enzyme activities. Bovine fetuin (Sigma) was used as the substrate to test
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fetuin protein products were compared to the untreated substrate by SDS-PAGE. and a 
shift in mobility o f the substrate indicated that the enzymes were active.
For enzymatic digestions o f the PSMA preparations, purified rPSMA (0.5pg) or 
lOpg o f LNCaP membrane extract was boiled at 100°C in denaturing buffer (0.5% 
SDS, 1% P-mercaptoethanol) for lOmin. After cooling on ice. 0.5% n-octyl P-D- 
glycopyranoside (Sigma, St. Louis. MO) was added, and the digestions were 
processed according to the manufacturers' specifications in a total volume of20f.il.
The enzymes and concentration used were as follows: Flavobacierium 
meningosepticum PNGaseF (Boehringer Mannheim. Indianapolis, IN): 1U: 
Flavobacierium meningosepticum Endo F/PNGase F (Oxford GlycoSciences. 
Wakefield, MA): 5U: Streptomyces plicatus Endo H (NEB. Beverly. MA): 500U: 
Clostridium perjringens sialidase (Sigma): 0 .12U; Jack bean P-galactosidase (Oxford 
GlycoSciences, Wakefield. MA): 0 .1U: Aspergillus oryzae P-N-acetylhexosaminidase 
(Sigma): 0.2U; Diplococctts pneumoniae endo-oc-N-acetylgalactosaminidase (Sigma):
1.5mU. A reaction without adding enzyme was prepared as a control to exclude the 
possibility o f nonspecific protein degradation during incubation. The reactions were 
overlaid with mineral oil. incubated overnight at 37°C. and subjected to Western blot 
analysis using PSMA specific MoAb 7E11.
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8. SELDI Immunoassay for PSMA
The SELDI ProteinChip® immunoassay for the detection and quantitation o f 
PSMA is illustrated in Fig. 5. One pg of Protein G (Sigma. St. Louis. MO) in 50mM 
sodium bicarbonate pH8.0 was immobilized on an 8-spot pre-activated ProteinChip 
array (Ciphergen Biosystems. Inc.. Fremont. CA) by incubating 2hr at RT with 
agitation. Residual active sites were blocked by incubating the entire array in 1M 
ethanolamine, pH 8.0 for 30min with agitation. The array was subsequently washed 
2x5min with 0.5% Triton X-100 (Sigma) in PBS. Ix5min with 0.1M sodium acetate.
0.5M NaCl. pH4.5, lx5min with 0.1M Tris HC1. 0.5M NaCI. pH8.0. and 2x5min with 
PBS. MoAb 7E11 (1.5pg) was added to the arrays and incubated at RT for 3hr. The 
unbounded antibodies were washed off by incubating the array 2x5min in 0.1% Triton 
X-100 in PBS. and 2x5min in PBS. A 96-well bioprocessor was assembled over the 
arrays, creating multiple sample wells in the format of a 96-well plate. To establish the 
rPSMA standard curve, 1 to 90ng of rPSMA was used in this study as the working 
range and applied to the arrays in 30pl o f PBS containing 0.1% Triton X-100. To 
detect PSMA in serum. 400pl o f diluted serum samples were applied to the arrays (1/2 
to 1/10 diluted in PBS with 0.5% Triton X-100 to obtain the mass signal o f PSMA 
within the working range of the standard curve). The samples were incubated 
overnight at 4°C with vigorous agitation. The array was subsequently washed 2x5min 
with 0.1% Triton X-100 in PBS. 2x5min with PBS. and briefly with HPLC H2O. 
Sinapinic acid (Ciphergen Biosystems) saturated in 50% (v/v) acetonitrile. 0.5% (v/v) 
trifluoroacetic acid and 0.05% Triton X-100 was used as the matrix solution, along













Fig. 5. Illustration o f the ProteinChip® SELDI mass spectrometry 
immunoassay used for the quantitation of PSMA in body fluids. Protein G 
is used to coat a pre-activated ProteinChip to immobilize MoAb 7E11. 
Recombinant PSMA or body fluid is applied to the chip array. The chips 
are washed to remove unbound materials, an energy absorbing molecule 
added, and the chip subjected to SELDI-TOF-MS to produce mass spectra 
o f the bound PSMA.
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with P-galactoglobulin (MW 18,363.3 Da) included as an internal standard (IS) for 
normalization. The matrix solution (2x0.5pl) was applied to the array, and the array 
was air dried at RT. The detection of serum PSMA was performed using the PBS-I 
mass reader (Ciphergen Biosystems) with a laser intensity o f 60. The data in each 
spectrum was averaged from 120 laser shots. The peak area o f either serum PSMA or 
rPSMA in each spectrum was normalized against the peak area o f IS. The PSMA/IS 
ratios were calculated and the levels of serum PSMA were determined by comparing 
the serum PSMA/IS peak area ratios to rPSMA/IS area ratios o f the standard curve. To 
assess the assay performance, a total of three averaged spectra were collected from 
each sample. The average and standard deviations were calculated to determine the 
intra-assay variability. A number o f serum samples were repeated on different days to 
assess the inter-assay variability.
9. Biostatistical Analysis
The differences o f PSMA levels among the normal and patient populations were 
analyzed using one-way ANOVA. First. Levene's test was performed to examine the 
homogeneity o f variances among the PSMA values o f normal and patient populations. 
If the equality o f variances was assumed (p-value >0.05). then student's t-test was 
performed to compare the differences of the PSMA levels. If the equality of variances 
could not be assumed (p-value <0.05). Tamhane's post hoc test was adopted to 
compare the differences o f the PSMA levels. In both student’s t-test and Tamhane’s 
test, the overall significance level was set at 5%.
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10. Total RNA Preparation and Northern Blot Analysis
LNCaP cells were grown as described in the section o f Cells and Cell Culture. The 
cells were cultured in 5% charcoal/dextran-treated FBS (stripped FBS) in the presence 
or absence o f R 1881 (1 .2  or4nM ). and/or EGF (20 or lOOng/ml). and/or 12-o- 
Tetradecanoylphorbol-13-acetate or TPA (0.1 or InM) for 48 hrs. At the end of the 
treatment, medium was aspirated. Cells were washed with PBS. scraped and pelleted 
by centrifugation at 300 x g  for 5 min. The supernatant was completely aspirated. The 
cell pellets were either stored at -80°C for later use or lysed directly in Buffer RLT in 
the RNeasy Kit (Qiagen, Santa Clarita. CA). Total RNA was extracted following the 
instructions o f the kit and stored at -80°C. For Northern blot analysis, fifteen pg of 
total RNA was fractionated in 1.1% agarose gel by electrophoresis and blotted onto 
positively charged nylon membranes (Roche Molecular Biochemicals. Indianapolis. 
IN). The RNA was immobilized on the membrane by UV crosslink. The membrane 
was pre-hybridized in ULTRAhyb™ hybridization solution (Ambion. Inc.. Austin. 
TX) prior to the addition o f the digoxigenin labeled PSMA probe for hybridization. 
The membrane was incubated with probe overnight at 68°C. After hybridization, the 
blot was washed 2 x 5min in 2xSSC, 0.1% SDS and 2 x 15min in O.lxSSC. 0.1% SDS 
at 68°C. Then the blot was incubated with anti-digoxigenin-AP Fab fragments (Roche. 
Indianapolis. IN) 1:10.000 diluted in blocking buffer and washed. To detect the PSMA 
mRNA band, C SPD ' Ready-to-Use chemiluminescent substrate was applied to the 
membrane, and the membrane was exposed to X-ray film at different lengths o f time.
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11. Construction of Luciferase Report Vectors
The published PSMA gene sequence can be found in GenBank (accession number 
AF007544) (12.30). The genomic sequence also includes approximately 2.4 kb of the 
5’ upstream region with the transcriptional initiation site identified at nt 2488. In order 
to analyze the PSMA promoter, a 2kb (nts 588-2522) and a 0.8kb (nts 1791-2522) 
fragment o f  the 5' regulatory region were subcloned upstream of the pGL2 basic 
luciferase vector (Promega). These constructs were designated as PI and P2. 
respectively. Also, to analyze the potential enhancer elements in the first intron. the 
corresponding region (nts 2876-4973) was subcloned further upstream o f the 0.8kb 
PSMA fragment (nts 1791-2522) in the pGL2 basic luciferase vector, and the 
construct designated as I/Pl. These vectors were gratefully provided by Dr. Antonia 
Vlahou. EVMS. The plasmids were purified using Qiagen EndofreerM plasmid 
preparation kit. and the sequence identities confirmed by sequencing analysis.
12. Transient Transfection of LNCaP Cells
LNCaP cells were seeded in 6-well plates 24 hrs before transfection at 5 x 105 
cells/well. The cells were approximately 70% confluent at the time o f transfection. For 
the purpose o f this study, six different transfection reagents including Transfast 
(Promega), Effectene (Qiagen) and Lipofectin (Gibco) Fugene 6 (Roche), Superfect 
(Qiagen) and LipofectAMINE (Gibco) were tested to optimize the transfection in 
LNCaP cells. Vector pEGFP-Cl (Clontech) is a plasmid that encodes GFP (green 
fluorescent protein) driven by human cytomegalovirus (CMV) immediate early 
promoter. It can constitutively express GFP upon entering mammalian cells, and
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therefore can be used as an indicator for successful transfection. To test the 
transfection reagents, DNA complex mixtures were prepared by mixing 2pg pEGFP 
plasmid DNA with each of the six different transfection reagents respectively. The 
transfections were proceeded according to the manufacturers' instructions. The 
expression of GFP was examined 24 to 48 hrs after transfection. The cells that have 
received and internalized pEGFP vector emitted bright green light under fluorescent 
microscope, whereas the untransfected cells remained dim. Fig. 6 summarizes the 
transfections with pEGFP vector in LNCaP cells using different transfection reagents. 
O f the six transfection reagents. Effectene. Transfast and Lipofectin showed the 
highest transfection efficiency. The same results were obtained with the transfections 
performed in RPMI 1640 medium containing either 5% stripped FBS or 5% stripped 
FBS plus 2nM R1881. Transfast was chosen for the current study because o f its high 
transfection efficiency and simple protocol.
Once the transfection conditions were perfected with pEGFP vector, the same 
protocol was used to introduce the luciferase reporter constructs containing PSMA 
promoter and/or enhancer into LNCaP cells to test their promoter/enhancer activities. 
LNCaP cells seeded in 6-well plates at 70% confluency were transfected with 2fig of 
PI. P2. I/Pl or pGL2-basic vectors and harvested at 48hrs after transfection. In order 
to examine the constructs’ responsiveness to androgens, the transfections were 
performed in RPMI 1640 medium containing 5% stripped FBS or 5% stripped FBS 
plus 2nM R1881. A pGL3-PSA luciferase reporter construct carrying a 5.8kb 
promoter/enhancer region of PSA gene (kindly provided by Drs. E. Keller and A. 
Mizokami) was used as the positive control for the promoter responsiveness to








Fig. 6. Comparison o f transfection reagents in LNCaP cells using GFP. GFP vector 
was transfected in LNCaP cells using six different transfection reagents. The cells 
were cultured in RPMI medium with 5% FBS and the transfection efficiency was 
determined under fluorescent microscope (4x) (right panel). The left panel shows 
the cell numbers under the normal phase (4x). Note that similar transfection 
efficiency was also observed in 5% charcoal stripped RPMI medium with or 
without 2nM R1881.
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androgen. To examine the direct involvement o f AP-1 proteins in the activation of 
PSMA promoter, the PSMA luciferase constructs were cotransfected with 2pg each of 
the pcDNA-cJun and/or pcDNA-cFos expression vector or the empty vector 
pcDNA3Z+ as negative control (vectors were provided by Dr. Timothy J. Bos at 
EVMS). The cotransfected cells were incubated in medium containing either 5% 
stripped FBS or 5% stripped FBS with 2nM R1881 and harvested at 48 hrs post 
transfection for luciferase assay. All transfections were repeated in triplicate in three 
independent experiments.
13. Luciferase Assay
Cells were harvested from 6-well plates 48hrs after transfection. Medium was 
removed by aspiration and cells washed with cold PBS. Cells were lysed in 150pl of 
lx Reporter Lysis Buffer (RLB) (Promega. Madison. WI), then frozen at -80°C. 
thawed and scraped to collect the lysates. After vortexing for 30sec. the lysates were 
centrifuged at 4°C. 12.000rpm for Imin. The luciferase activity in 20pl o f the 
supernatant was measured using TD20/20 luminometer (Turner Design) and 
normalized using the amount of total protein in the cell lysates. The luciferase activity 
of the PSMA promoter constructs was presented as the fold of induction over the 
pGL2-basic vector.
14. Preparation of Nuclear Extracts
LNCaP cells from one T75 flask were washed 2x briefly with cold PBS. scraped 
and harvested by centrifugation at 1500rpm for 5min. PBS was removed and the cells
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were resuspended in cold lOmM HEPES pH7.9, 1.5mM MgC^, lOmM KC1. 0.5% 
Igepal (Sigma), lx  Complete™ Proteinase Inhibitor Cocktail (Roche). ImM PEFA 
(Roche). 0.5mM DTT. Cells were incubated on ice for lOmin with gentle pipetting up 
and down 2x at 5min increments, and centrifuged at 4°C. 14.000rpm for lOmin. The 
supernatant was discard and the pellet was resuspended in 20mM HEPES pH 7.9. 25% 
glycerol. 0.42M NaCl. 1.5mM MgCL. 0.2mM EDTA. lx  Completem  Proteinase 
Inhibitor Cocktail. ImM PEFA, 0.5mM DTT. Cells were incubated on ice for 30min 
with gentle pipetting up and down 2x at 5min increments, and centrifuged at 4°C. 
14,000rpm for 30min. The supernatant was dialyzed against 20mM HEPES pH 7.9. 
20% glycerol, 0.1M KC1, 0.2mM EDTA, ImM  PEFA, 0.5mM DTT at 4°C in porous 
membrane tubing (MWCO 12-14,000: flat width: 10mm; Spectra/Por) for 4 hrs with 1 
change at half way point. Lysates were removed from tubing, transferred to eppendorf 
tubes in 25pl aliquots, quick frozen on dry ice and stored at -80°C. The protein 
concentration was determined by the BCA protein assay (Pierce Chemical. Rockford. 
IL).
15. Synthesis o f DNA Probe for EMSA
Oligonucleotide probes were generated from overlapping primer sets synthesized 
by GibcoBRL/Life Technologies. The probes included 3 putative AP-1 binding sites 
from the PSMA promoter region, a consensus AP-1 site (PG32-1). 3 AP-1 like sites 
(PG32-1 mutants), an androgen responsive element (ARE), a mutant ARE and a CMV 
heteroligonucleotide. The primer sets were as follows with the core AP-1 or ARE site 
shown in underlined base pairs:
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PSMA 1:
Forward Primer 5 ' TTCAAGCGATTCTCCTGCCTCAGC 3'
Reverse Primer 5' TACTCAGGAGGCTGAGGCAGG 3’
PSMA 2:
Forward Primer 5’ TCTGCTCTGCTTTTATTCAGT 3 '
Reverse Primer 5 ' TCT AC AAT ACTCT ACT G AAT A A 3*
PSMA 3:
Forward Primer 5’ T AG AATTT C AG AGTT G AAT AAA 3"
Reverse Primer 5’ TTATGAGGAACTTTTATTCA 3*
PG32-1:
Forward Primer: 5 ' ACCCGGGGATCCTCTAGAATGACTCATCGG 3' 
Reverse Primer: 5’ CTTGCATGCCTGCAGGATCCGATGAGTCAT 3' 
PG32-1 mut-1:
Forward Primer: 5 ' ACCCGGGGATCCTCTAGAATGACCCATCGG 
Reverse Primer: 5’ CTTGCATGCCTGCAGGATCCGATGGGTCAT 3* 
PG32-1 mut-2:
Forward Primer: 5’ ACCCGGGGATCCTCTAGAATGACGCATCGG 3' 
Reverse Primer: 5* CTTGCATGCCTGCAGGATCCGATGCGTCAT 3' 
PG32-1 mut-3:
Forward Primer: 5’ ACCCGGGGATCCTCTAGAATGACACATCGG 3* 
Reverse Primer: 5’ CTTGCATGCCTGCAGGATCCGATGTGTCAT 3' 
PSA ARE:
Forward Primer 5’ TTGCAGAACAGC 3*
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Reverse Primer 5’ GAGCTAGCACTTGCTGTTCT 3'
PSA mutant ARE (mARE):
Forward Primer 5’ TTGCAAAAAAGC 3’
Reverse Primer 5* G AGCT AGC ACTTGCTTTTTT G 3’
CMV Hetero-oligo:
Forward Primer: 5’ TTGACGTCAATAATGACG 3'
Reverse Primer: 5’ TATGGGAACATACGTCAT 3’
For each probe, the primer set was first allowed to self anneal at 48°C for lOmin in 
the mixture o f dATP (for unlabeled probe) or [a-32P]ATP (for labeled probe) and 
dTTP, dCTP. dGTP. Klenow Fragment o f DNA polymerase I (3 ’> 5' exo’) (NEB) was 
added to the mixture and the reaction was incubated at 16°C for 1 hr. The probe was 
phenol-extracted and then purified on a Chroma Spin TE 10 column (Clontech). The 
32P incorporation was estimated using liquid scintillation counter. The labeling 
efficiency was obtained at >l,000.000cpm/pl. The probes were stored at -20°C.
16. Electrophoretic Mobility Shift Assay (EMSA)
Gel mobility shift assays were based on the conditions described by Hadman et al 
(60) with slight modifications. Ten to fifteen pg of nuclear extract and lpg  o f poly 
(dl.dC) (Amersham Pharmacia) were added to the binding buffer containing lOmM 
HEPES pH 8.0, 17.5% glycerol (v/v). O.lmM EDTA. 20mM NaCl. 4mM M g C b .
2mM Spermidine (Sigma) and 2mM DTT (Gibco). The mixture was preincubated on 
ice for 20min. Approximately 50,000cpm o f the labeled probe was added to each
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reaction and incubated on ice for 20min. The reaction was loaded onto a 6% (59:1) 
acrylamide gel and run with lxTBE buffer at 20mA. The gel was dried in vacuum gel 
drier at 80°C for lh r and exposed to X-ray film for autoradiography. For cold probe 
competition assays, unlabeled probes were added in 50- or 100- fold excess during 
preincubation. For antibody competition assays, 0.5 to 2pg of antibody was added 
during the 20min preincubation or after the addition o f labeled probe followed by 
15min incubation on ice.




A. EXPRESSION AND PURIFICATION OF RECOMBINANT PSMA 
1. Construction o f pBlueBacHisB-PSMA Transfer Vector
Fig. 7A shows the map of pBlueBacHisB-PSMA construct. The pBlueScript- 
PSMA transfer vector was constructed by RT-PCR cloning o f the full length PSMA 
cDNA from LNCaP cell mRNA. The subsequent PCR step o f adding BamHI and 
Hindlll restriction sites to the 5' and 3' ends o f PSMA fragment is shown in Fig. 7B. 
The amplified product was then conveyed from the pGEMT vector into the 
pBlueBacHVsB vector linearized with the restriction enzymes BamHI and Hindlll. The 
restriction digestion o f pBlueBacHisB-PSMA construct showed the existence of 
2.65kb PSMA cDNA (Fig. 7C). Partial sequencing confirmed the correct PSMA 
coding region with the 6x histidine tag at its amino terminus.
2. Generation and Identification of rPSMA Baculovirus
The strategy used to generate and identify rPSMA baculovirus is outlined in Fig. 8. 
First, insect cells were cotransfected with pBlueBacHisB-PSMA plasmid and the 
linearized wild-type AcMNPV DNA. Forty eight hours after transfection, the media 
from the transfected plates were harvested and used as initial viral stock in the plaque 
assay to select rPSMA baculovirus. Because the in vivo homologous recombination 
would add a promoter to drive the Laz gene expression in the linearized baculovirus
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Fig. 7. Construction o f pBlueBacHisB-PSMA transfer vector.
A, A map o f pBlueBacHis-PSMA transfer vector. PH, polyhedrin gene promoter;
(His)6, six histidine tag fused to 5’ end o f PSMA gene; Xpress MoAb Epitope, 
recognition site for the Anti-Xpress MoAb that dectects (His)6-fusion protein.
B, PCR amplification o f PSMA cDNA from pBlueScript phagemid vectors. Lane I, 
l kb DNA ladder; Lane 2, amplified products from a randomly isolated pBlueScript 
plasmid showing nonspecific amplification; Lane 3, amplified products from 
pBlueScript-PSMA. The arrow indicates the 2.65kb PSMA amplified product.
C, Restriction digestion o f pBlueBacHis-PSMA with BamHI and Hindlll. Lane I, 
l kb DNA ladder; Lanes 2 and 3, 5pg or 1 jag o f pBlueBacHis-PSMA plasmid 
digested with BamHI and Hindlll. The arrows indicate the 10.3kb linearized 
pBlueBacHisB vector and the 2.65kb PSMA restricted fragment.







Cotransfection of sf9 cells (homologous recombination)
41
Plaque purification using x-gal to obtain 
recombinant baculovirus with PSMA gene
&
PCR to verify the insertion of PSMA gene in viral genome
- a
Generation of high titer recombinant viral stock
-a
Time course study; determine the localization of rPSMA
41
Large scale rPSMA expression in Hi5 cells
41
Cell harvest; rPSMA solubilization
■ a
Protein purification using Cobalt affinity column
Fig. 8. A schematic diagram outlining the strategy for expression and 
purification of recombinant PSMA using baculovirus /insect cell system.
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DNA. the active P-galactosidase would be produced along with the recombinant 
protein. Thus, by using the chromogenic substrate x-gal in the agarose medium, the 
recombinant PSMA viruses were visualized as the blue and occlusion body negative 
plaques (Fig. 9A). Four rounds o f  plaque assays were repeated to ensure the purity o f 
the rPSMA baculovirus. To further rule out any false positives. PCR analyses were 
performed on putative rPSMA viral DNA (Fig. 9B). Since the primers flanked the 
polyhedrin gene, the wild type polyhedrin gene fragment without the rPSMA insert 
was amplified as a 630bp band, whereas the rPSMA insert was shown as a 3.2kb 
amplified fragment. Therefore, the PCR result confirmed the correct insertion of the 
2.65kb PSMA gene behind the polyhedrin promoter.
The expression of rPSMA protein was monitored by Western blot analyses using 
antiXpress (Invitrogen. Carlsbad. CA) and PSMA specific MoAb 7E11. AntiXpress 
recognizes the enterokinase digestion site at the amino terminus o f the Histidine- 
tagged proteins expressed from the pBlueBacHisB vector (Fig. 7A). whereas the 
epitope for 7E11 is located at the first 6 amino acids of the amino terminus o f PSMA 
(15). Fig. 10 shows that both antibodies detected predominantly a lOOkDa protein 
band in the recombinant virus infected cells (lane 4, Fig. 10A and B), but not in the 
uninfected (lane 1) or the wild type virus infected insect cells (lane 2). After being 
expressed. rPSMA remained located in insect cells, and was not secreted in the cell 
culture medium (lane 3). Like the native PSMA from LNCaP cells (14). a 200kDa 
dimer o f rPSMA was detected in high protein concentration of insect cell lysates (lane 
5, Fig. 10A). Note that the 45kDa band detected by 7E11 was likely due to the 
proteolytic degradation in the crude insect cell lysates or an artifact in SDS-PAGE
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Fig. 9. Generation o f  recombinant PSMA baculovirus.
A, A recombinant PSMA baculovirus plaque shown in plaque assay.
B, PCR analysis verified the insertion o f PSMA gene into 
baculovirus genome. Baculovirus DNA was isolated from the 
infected insect cells and subjected to PCR analysis using primers 
specific to the 5’ and 3’ ends o f the polyhedrin gene. The amplified 
product was run on 1% agarose gel and stained with ethidium 
bromide. Lane I, lkb DNA ladder; Lane 2, pBlueBacHis-PSMA 
restricted by BamHI and Hindlll; Lanes 3 and 4, amplified product 
from the rPSMA baculovirus DNA; Lanes 5 and 6, amplified 
product from the wild type baculovirus DNA. The 3.2kb product 
represents the rPSMA baculovirus and 630bp product is derived 
from the wild type baculovirus.
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Fig. 10. Western blot analysis to detect the expression of rPSMA. Hi5 insect 
cells were infected with wild type or rPSMA baculovirus. PSMA expression in 
whole cell lysate (WCL) and culture medium was analyzed using MoAb anti­
Xpress (A) or 7E11 (B). Lane 1. uninfected Hi5 cells; Lane 2, wild type virus- 
infected WCL; Lane 2, rPSMA virus-infected culture medium; Lane 4 , rPSMA 
virus-infected WCL 2pg; Lane 5 (only with MoAb anti-Xpress), rPSMA virus- 
infected WCL 5pg.
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sample preparation (61). Taken together, Western blot analyses demonstrated that 
rPSMA was correctly expressed in the insect cells, and also implied that the addition 
o f  six histidine amino acid residues to the amino terminus o f PSMA did not mask or 
interfere with the epitope recognized by MoAb 7E11.
3. Optimization of rPSMA Expression
To determine the rPSMA expression conditions, time course experiments were 
performed on insect cells infected with recombinant baculovirus at different MOI and 
the amounts o f rPSMA expressed were analyzed at 24-hr intervals (Fig. 11). Increased 
MOI from 1 to 5 did not seem to alter the expression o f rPSMA. as the expression 
peaked at 48 hrs post infection (p.i.). regardless o f the MOI. This was followed by a 
decrease, possibly due to the rapid degradation of rPSMA as a foreign protein in insect 
cells. By 96 hrs p.i. rPSMA was detected in culture medium accompanying cell lysis. 
Therefore, the optimal expression conditions were to infect cells at a MOI o f 5 and to 
harvest at 48hr post infection.
4. Large Scale Expression and Purification of rPSMA
Large-scale rPSMA expression was carried out in monolayer cell culture, since it 
had previously been shown that the Hi5 insect cells appeared to provide better 
glycoprotein expression levels in monolayer cultures (62). Because PSMA is a heavily 
glycosylated transmembrane protein, lysis buffer containing the detergents SDS and 
Igepal was required for solubilization. Purification o f rPSMA was performed using a 
cobalt affinity column and imidizole gradient elution, resulting in a rPSMA elution
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Fig. 11. Time course and cellular localization study of recombinant PSMA 
expression. Hi5 insect cells were infected with rPSMA viral stock at MOI 1. 
2.5 and 5. Infected cells were harvested from day 1 to day 4. Both whole cell 
lysate and medium were subjected to Western blot analysis using 7E11. Cell 
membrane extract from LNCaP was used as positive control and uninfected 
Hi5 cells were used as negative control.
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Elution
Fig. 12. Purification o f  recombinant PSMA using Cobalt affinity 
chromatography. The WCL (0.5pg), flow-through and eluted fractions (20|il) 
were analyzed on a 10% SDS-PAGE followed by silver staining. IMD , imidizole.








peak in the 50mM imidizole fractions (fraction #3 in 50mM imidizole. Fig. 12). In 
addition to the lOOkDa rPSMA commonly shown in all eluted fractions, the 200kDa 
rPSMA was also readily detected by silver stain in the elution peak. The pooled 
rPSMA containing eluants were dialyzed to eliminate the interference o f imidizole 
with protein quantitation in the BCA assay. Approximately 0.5 mg of rPSMA protein 
was obtained from 30mg o f insect cell crude lysate using 1ml of the cobalt affinity 
resin, to give a final yield o f 1.67% (i.e. the amount o f rPSMA/ the amount of crude 
lysates).
5. Characterization of rPSMA
Purity and molecular size SDS-PAGE and Western blotting were run in parallel 
to analyze the purity o f rPSMA in the final product (Fig. 13A and B). In addition to 
the major lOOkDa rPSMA band (lanes 1 and 2. Fig. 13A). another closely migrating 
> lOOkDa band and a band of approximately 190kDa were also observed by silver 
staining when doubling the amount o f rPSMA applied to the gel (lane 1. Fig. 13A). 
Since all the lOOkDa and 190kDa species were readily detected by the 7E11 antibody 
(lanes 1 and 2, Fig. 13B), the two lOOkDa bands were likely due to the slight 
differences in glycosylation (refer to the data in Fig. 14), whereas the 190kDa protein 
most likely represents a high molecular weight rPSMA formed at high concentration. 
The latter species has also been detected in native PSMA preparations (14). The purity 
and molecular size o f  rPSMA was further confirmed by mass spectrometry by 
applying the rPSMA directly to a Ni++-coated IMAC ProteinChip®. As shown in Fig.
13C, the purified rPSMA protein product was accurately detected with an observed
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Fig. 13. The purity o f rPSMA. A, Recombinant PSMA was detected on a 10% 
SDS-PAGE gel by silver staining. Lane 1, 0.5pg of rPSMA; Lane 2, 0.2pg o f 
rPSMA. A single band of approximately lOOkDa was shown in low 
concentration, which was more pronounced as a doublet band in high 
concentration (arrow). A PSMA dimer (190kDa) was also detected in higher 
protein concentration (arrowhead). B, A Western blotting using 7E11 run in 
parallel with silver staining showed both the 100 kDa and 190 kDa rPSMA 
species. The amounts of rPSMA in lanes 1 and 2 were the same as in (A). No 
other contaminants were detected. C, Recombinant PSMA was applied directly 
to a Ni++-coated IMAC ProteinChip® and the chip subjected to SELDI-TOF- 
MS. A peak o f the correct mass o f  (101129Da) was observed. Also observed 
was a second peak, which is the doubly charged PSMA species (50544Da).
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mass o f 101129.2Da. The peak at 50544.2Da represents the doubly charged rPSMA, 
i.e. a signal generated at half the mass/charge value o f the singly charged PSMA 
species. Collectively the silver stained gel. immunoblotting and mass spectrometry 
demonstrate that the rPSMA has been purified to near homogeneity and was o f the 
predicted molecular size.
Glycosylation Because native PSMA is a glycoprotein (16), and rPSMA was 
observed to have approximately the same molecular size as the native PSMA. we 
compared the extent o f glycosylation in the rPSMA with the PSMA derived from 
LNCaP cells, i.e. the native PSMA. A series of glycosidase digestions were performed 
on rPSMA and the digests were analyzed by Western blotting using MoAb 7E11. Fig. 
14A shows the change o f rPSMA molecular weight upon digestion with 
endoglycosidases specific for N-glycans. Recombinant PSMA was completely 
deglycosylated by PNGase F (PF). endo F/PNGaseF (F/PF) and at least partially 
deglycosylated by endo H (H), resulting in a nonglycosylated form of PSMA with an 
approximate size o f 86kDa (1 anes 2. 3 and 4, Fig. 14A). The sensitivity to endo H 
indicated that the N-glycans on rPSMA are mainly the high mannose type. This 
observation was further confirmed by the resistance of rPSMA to a variety of 
complex-type specific cxoglycosidases such as sialidase (S). (i-galactosidase (G), (3-N- 
acetylhexosaminidase (AH) and various combinations (Fig. 14B). Note that the endo 
H treated rPSMA was slightly larger than the completely deglycosylated form (lane 4 
compared to lanes 2 and 3, Fig. 14A). This suggests that besides being modified 
mainly with the high mannose type N-glycans, the rPSMA protein might also contain
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Fig. 14. Glycosylation analysis o f rPSMA. Purified rPSMA or LNCaP 
membrane extracts were digested with endo- or exoglycosidases. and the digests 
were analyzed by Western blotting using MoAb TEW. A,  Digestion with 
endoglycosidases specific for N-glycans. Lanes I to 4, rPSMA; Lanes 5 to 8, 
LNCaP membrane extracts; C, control without enzyme; PF , PNGase F; F/PF, 
endo F/PNGase F; H, endo H. Note that PNGase F and endo F/PNGase F 
cleaved both recombinant and LNCaP derived PSMA, resulting in an 86kDa 
band (large arrow). Endo H cleaved most if not all the carbohydrates from 
rPSMA, while it only slightly cleaved LNCaP derived PSMA {small arrow).
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Fig. 14. (Continued) B, Digestion o f rPSMA with exoglycosidases. C, 
control without enzyme; S, sialidase; G, P-galactosidase; S+G, sialidase/p- 
galactosidase; S+G+AH, sialidase/p-galactosidase/p-N- 
acetylhexosaminidase. All the exoglycosidases were proven to be active in 
the control tests (refer to materials and methods; data not shown). C, 
Digestion o f rPSMA with endoglycosidases specific for O-glycans. C, control 
without enzyme; S+O, sialidase/endo-a-N-acetylgalactosaminidase: O , endo- 
a-N-acetylgalactosaminidase. Note that none of the glycosidases used in B 
and C were capable of stripping the carbohydrates from rPSMA or reducing 
the molecular size o f the lOOkDa rPSMA (small arrow). D, Digestion of 
bovine fetuin as the positive control for sialidase and O-glycanase. C, 
substrate only; S: sialidase; O, endo-a-N-acetylgalactosaminidase; S+O, 
sialidase / endo-a-N-acetylgalactosaminidase. The digests were resolved by 
SDS-PAGE and stained with Coomassie blue. The increases in mobility of 
fetuin indicated that the enzymes in the experiment were active.
Table 2 Glycosylation o f  rPSMA







0-1 inked glycans a C -
° not available. 
b +, present. 
c not present.
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a very small portion o f the complex type N-glycans but which did not cause a 
significant mobility shift after cleavage by the specific exoglycosidases (Fig. 14B).
On the other hand, native PSMA from LNCaP cells was completely 
deglycosylated by PNGase F and endo F/PNGaseF. and showed a major, if not 
complete resistance to endo H (lane 8 compared to lanes 6 and 7. Fig. 14A). 
suggesting that the N-glycans o f native PSMA are mainly composed o f complex type 
N-glycans with possibly a minor fraction o f the high mannose type. Taken together, 
the N-glycan profiles o f rPSMA and native PSMA seem to be different, with rPSMA 
being composed predominantly o f the high-mannose type glycans.
Since the native PSMA in LNCaP cells were shown to lack O-glycans (16). it was 
o f interest to examine whether O-glycans were also absent in rPSMA. Digestion with 
endo-a-N-aectvlgalactosaminidase alone (O) or in combination with sialidase (S+O) 
caused no molecular weight changes (lanes 2 and 3 compared to lane 1. Fig. 14C). The 
glycosidases used in this experiment were shown to be active using fetuin as the 
substrate (Fig. 14D). Therefore the result indicates that O-glycans are absent in 
rPSMA. The result o f glycosylation analysis is summarized in Table 2.
Immimogenicity MoAbs 4G5 and 4G7 were second generation MoAbs 
produced in our laboratory using purified native PSMA (Wright, et al. unpublished 
data). MoAb J591. which recognizes an epitope on the extracellular domain of PSMA. 
was kindly provided by Dr. Neil Bander at Cornell University (20). These antibodies 
and 7E11 were used to perform Western blot analyses to determine if rPSMA could be 
recognized by MoAbs to both the intracellular and extracellular domains o f PSMA.
Fig. 15 shows that like native PSMA, rPSMA was bound by all four antibodies, with
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Fig. 15. Western blot analysis o f rPSMA. MoAb 7EII and two second 
generation MoAbs, 4G5 and 4G7, which recognize the intracellular 
domains o f PSMA, and J591 which recognizes the extracellular domain 
were used. Lane I, uninfected insect Hi5 cells; Lane 2, rPSMA; Lane 3, 
LNCaP membrane extracts. All four MoAbs identified the lOOkDa 
rPSMA, whereas the 200kDa PSMA dimer was detected by 7E11 ,4G5 
and 4G7.
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the major lOOkDa protein detected. The minor 200kDa species was also detected by 
7E11. 4G5 and 4G7 but not by J591, probably due to the different affinities to the 
rPSMA dimer. Since these antibodies are specific for multiple intra- and extracellular 
regions o f  the PSMA polypeptide backbone, the results indicate that the baculovirus 
rPSMA possesses the correct peptide sequence and similar immunoreactivity to native 
PSMA. despite the differences in glycosylation. Moreover, because of the similarity in 
immunoreactivity between the native and recombinant PSMA. rPSMA can be used as 
the purified substitute antigen in developing immunoassay for PSMA.
B. DEVELOPMENT OF PSMA SELDI IMMUNOASSAY
1. Optimization of Conditions for PSMA SELDI Immunoassay
ProteinChip* SELDI technology offers a novel approach for the development of 
immunoassay. Since the conditions for SELDI immunoassay have not been 
established, the following parameters were determined to optimize the assay:
PSM4 Specific Antibody MoAb 7E11 (II) .  J591. and 107-1A4 (provided by Dr. 
R. Vessella at the University o f Washington) (63). and rabbit polyclonal antibodies 
PSM#1 and PSM#2 (kindly provided by Dr. S. L. Su at Northwest Biotherapeutics. 
Inc.) are PSMA specific antibodies. Since different antibodies recognize the same 
PSMA protein with different specificities and affinities, these antibodies were 
compared in order to determine which has the highest affinity for capturing both the 
native PSMA and rPSMA. Out o f these five antibodies, 7E11 and 107 showed higher 
affinities than the other three antibodies. Fig. 16 illustrates the comparison of the














Fig. 16. Comparison o f the antigen capturing efficiency o f PSMA specific 
antibodies in SELDI immunoassay. Two antibodies (7E l 1 and 107) were 
immobilized on PS-1 chips. The whole cell lysate from LNCaP cells which 
express PSMA was used as the source o f antigen (Ag). +, LNCaP whole cell 
lysate added; dilution buffer only (0.1% Triton X-100 in PBS). Note that 
beside the 101 kDa PSMA captured by both antibodies (arrows), an 89,470Da 
protein was also detected by 107 (block arrow), which is likely to be PSMA’, 
the splicing variant o f PSMA.
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PSMA peaks in the spectra obtained by 7E11 and 107. Both 7E11 and 107 were able 
to capture PSMA from LNCaP cell lysate. In addition to the 101 kDa PSMA detected 
by both antibodies, an 89kDa protein was also detected using 107. Since the PSMA 
peak area was to be used for the quantitation o f PSMA, the presence o f the 89kDa 
peak might compromise the definition o f the 101 kDa peak area (Fig. 16 and the 
bottom panel of Fig. 17). Therefore. 7E11 was selected for further evaluation in 
PSMA immunoassay development.
Chip Surface Chemistry PS-1 and PS-2 are two types o f preactivated protein 
chips manufactured by Ciphergen. Although both chips can covalently immobilize 
protein for the subsequent capture o f another protein that has affinity to the first one. 
e.g. protein G and antibody, the chemistries o f the two chips differ. Carbonyl 
diimidazole moieties were the active sites on the PS-1 chips, and the epoxy groups on 
the PS-2 chips. For this reason, they offer different efficiencies in protein 
immobilization and sensitivities in protein binding. Therefore it is necessary to 
compare these two chip types to maximize the coating o f protein G and to obtain 
better sensitivity in PSMA detection. As shown in Fig. 17. when LNCaP cell lysate 
was serially diluted and applied to PS-1 and PS-2 chips with 7E11 or 107. the 
difference in peak detection was apparent. At the same protein concentration, the 
intensity of the 101 kDa PSMA peak was much higher on the PS-1 chip (left panel) 
than on the PS-2 chip (right panel). Moreover, the serial dilution of antigen revealed a 
better linearity on the PS-1 chip. Therefore the PS-1 chip was chosen as the surface for 
PSMA SELDI immunoassay.
















Fig. 17. Comparison o f the ProteinChip* surface chemistries in PSMA SELDI 
immunoassay. Two antibodies (7E l l  and 107) were immobilized on PS-1 or 
PS-2 chips. The whole cell lysate from LNCaP cells was used as the source o f 
antigen (Ag) and applied to the chip in serial dilution (wedge, from 6, 12,25 
to 50ng/pl). Note that higher intensities were obtained on PS-1 chips than on 
PS-2 chips. Beside the 101 kDa PSMA captured by both antibodies (arrows), 
an 89,470Da protein was also detected by 107 (block arrow).
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Antigen Capture The next step was to determine the antigen capture capacity of 
the PS-1 chip. After coating the chip with protein G and MoAb 7E11. 15 to 90 ng of 
purified rPSMA was applied to the chip. Post-assay rPSMA samples were retrieved 
and analyzed along with pre-assay samples using 7E11 Western blotting. Fig. 18 
showed that the 7E11 based SELDI immunoassay was capable o f capturing up to 90ng 
o f rPSMA with the saturation still not being reached. The result provided an 
estimation of the antigen capture capacity o f the PS-1 chip array that was helpful for 
establishing standard curve.
Standard Curve To establish a standard curve for PSMA SLEDI immunoassay, 
pure rPSMA was serially diluted, immunocaptured on the PS-1 chip array, and 
subjected to mass analysis. Fig. 19A shows that 1 to 50ng o f rPSMA was readily 
detected at the molecular size o f 101 kDa. By plotting the rPSMA concentration versus 
the normalized peak area ratio between PSMA and the internal control (P- 
galactoglobulin), a rPSMA linear standard curve was generated with R2 of 0.985 (R2: 
the square of the correlation coefficient or the strength o f the association) and CV of 
8.9% (CV: the coefficient o f variation; used as a gauge o f the accuracy of the standard 
curve) (Fig. 19B).
Specificity o f  antigen capture from  serum To further examine whether PSMA
can be selectively captured and quantitated in complex body fluids. SELDI 
immunoassay for PSMA was performed using the serum samples from a patient with 
pathologically confirmed BPH and a patient diagnosed with advanced (stage T3) 
prostate cancer (PCA). These two serum samples were selected because they were 
known to contain different levels o f PSMA by Western blot analysis (27). Fig. 20
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
56
rPSMA (ng)
90 60 30 15 90 60 30 15
100kD—
Before After
Western Blot a  7E11
Fig. 18. The capture o f rPSMA on PS-1 chip. Western blot analysis 
showing the amount o f rPSMA added to the chip array (Before) and the 
amount o f rPSMA remaining in the supernatant after incubation {After). 
This analysis shows that up to 90ng o f rPSMA could be bound to the 
array.
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Fig. 19. The standard curve of rPSMA in SELDI immunoassay. Different 
concentrations o f rPSMA or serum were applied to pre-activated PS1 ProteinChips® 
containing bound MoAb 7E11, the chips were washed and subjected to SELDI 
mass analysis. A, Spectra of the rPSMA (1 to 50ng) showing that both the increases 
in intensity and peak area correlated with the amount o f antigen. B, Recombinant 
PSMA standard curve. Recombinant PSMA signal intensity of each spectrum 
shown in (A) was normalized to the internal standard (P-galactoglobulin,
25fmol/pl). A linear curve was generated by plotting the peak area ratio 
(rPSMA/intemal standard) versus the amount o f  rPSMA. The mean and standard 
deviation o f three separate mass spectra is shown.
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Fig. 20. PSMA detected in a serum sample from a patient diagnosed with 
prostate cancer (PCA). The analysis was the same as used for generating 
the rPSMA standard curve, except that lOOfmol/pl p-galactoglobulin was 
spiked as the internal standard for normalization. Doubling dilutions (i.e. 
10, 20, and 40 pg/pl) o f  total serum proteins show a linear regression. The 
mean and standard deviation o f three separate mass spectra is shown.
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shows the detection o f PSMA from the PCA patient. Like pure rPSMA, serum PSMA 
was also efficiently captured, even when the total serum protein concentration was 
diluted as low as lOpg/pl, which is approximately a 1:10 (v/v) dilution. The linear 
relationship between PSMA signals and serum protein concentrations (R2=0.980. 
CV=11.4%) suggests that the immunocapture o f PSMA from a complex mixture was 
specific. The serum PSMA peak intensity detected by SELDI correlated with the 
relative integral intensity o f PSMA of the same samples obtained by Western blot 
analysis (27), with the PCA sample having approximately two-fold greater amount of 
PSMA than the BPH sample. These preliminary data suggest that using the rPSMA as 
a standard antigen, PSMA in body fluids can be directly quantitated by the SELDI 
immunoassay at subnanomolar levels.
2. Quantitation o f the Serum PSMA Levels
After the assay conditions were optimized, the SELDI immunoassay was used to 
detect and quantitate PSMA in serum from 24 normal males donors (12 age <50; 12 
age >50). and from 10 BPH. 17 PCA (stage T1 to T3). and 9 prostatitis patients. The 
demographics o f  the healthy donors and patients are summarized in Table 3. Fig. 21 
shows the representative mass spectra o f the lOlkDa PSMA peak detected in serum 
from a normal age-matched donor, and in sera from patients with BPH. PCA or 
prostatitis. The intra-assay variability o f serum samples ranged from 1.2% to 20.1% 
with an average o f  10.1%. whereas the inter-assay variability ranged from 2.9% to 
18.7% with an average o f 11.8%.The serum PSMA levels for the different test groups 
are summarized in Fig. 22. The average level o f serum PSMA was 117. lng/ml in







Fig. 21. Representative example o f the mass spectrum obtained from the 
PSMA SELDI immunoassay. The lOlkDa PSMA peak was captured by 
7E11 and detected in the spectra o f the normal, BPH, PCA and 
prostatitis serum samples. When mouse IgG was substituted for 7E11, 
no PSMA was captured from the PCA serum sample {PCA/IgG). 
Normalized intensity, the intensity o f the protein peaks after 
normalization using P-galactoglobulin (MW 18,363.3Da) as the internal 
standard; Mass/Charge (kDa), the protein mass (kDa). The mass range 











Normal Male BPH PCA Prostatitis 
<50 >50
# of samples 
Mean (ng/ml)
12 12 10 17 9
272.9 359.4 117.1 623.1 119.9
Fig. 22. Comparison of serum PSMA levels in normal male 
donors and patients with BPH, PCA or prostatitis. Bars, the mean 
PSMA levels in the different test groups.
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Table 3 Demographics, serum PSA and PSMA levels, and statistical data fo r all
study groups
Normal Male
<50 >50 BPH PCA Prostatitis
Number of samples 12 12 10 17 9
Age
Range (yr) 2 7 -39 54-71 54-81 55-93 52-70
Average (yr) 33 .9 60 .3 6 8 .7 68 .5 62.2
SD 4.1 4 .8 8 .0 8.7 5.8
PSA value
Range (ng/ml) 0 .4 -1 .9 2 0 .7 3 -3 .3 2 0 .2 -1 3 .7 2 .4 -1 2 3 0 0 .5 -5 .6
Average (ng/ml) 0 .96 1.52 4 .8 6 107.15 1.58
SD 0 .6 0 .9 4 .2 309.1 2.0
PSMA value
Range (ng/ml) 106 .4 -576 .9 159 .8 -611 .5 3 5 .6 -1 9 3 .8 3 4 9 .5 -9 4 6 .6 73 .4 -168 .2
Average (ng/ml) 2 72 .9 3 59 .4 117.1 623.1 119.9
SD 145.2 149.3 4 8 .7 177.7 36.7
P  (normal <50)a -- 0 .83 0 .0 4 < 0 .0 0 1 0.04
P  (normal >50)* 0.83 - <0.01 <0.01 0.001
P  (BPH)C 0 .04 <0.01 — < 0 .0 0 1 1.00
P  (PCAt'7 <0.001 <0.01 <0.001 - < 0 .0 0 1
a P , normal m ale < 5 0  vs. each o f  the other groups 
b P , normal m ale > 5 0  v.v. each o f  the other groups 
c P .B P H  v.v. each  o f  the other groups 
d P . PCA vs. each  o f  the other groups 
N o com parison
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patients with BPH, 119.9ng/ml with prostatitis. 272.9ng/ml and 359.4ng/ml for normal 
men age <50 and >50, respectively, and 623.1 ng/ml for patients with PCA.
Statistical analysis of the data is summarized in Table 3. Due to the varied 
distribution o f PSMA levels in different populations, the equality o f  variances was not 
assumed. Therefore Tamhane's post hoc test was adopted to analyze the differences of 
PSMA values among different populations. The average serum PSMA level in older 
normal males (age >50) was slightly higher than that in the younger normal males (age 
<50), and the difference was not significant (p=0.83). On the other hand, significant 
differences were found when comparing the average PSMA level o f  either the normal 
population versus PCA (normal<50 vs. PCA: p<0.001; normal>50 vs. PCA: p<0.01). 
normal versus BPH (normal<50 vs. BPH: p=0.04; normal>50 vs. BPH: p<0.01). and 
BPH versus PCA (p<0.001). In addition, the mean level o f serum PSMA in prostatitis 
patients differed from that of the normal and PCA groups (normal<50 vs. prostatitis: 
p=0.04: normal>50 vs. prostatitis: p=0.001: PCA vs. prostatitis: p<0.001). but not 
from the BPH group (p= 1.00).
PSMA serum levels in individual patients with BPH and PCA are shown in Table 4 
and Table 5. These two populations were age matched (BPH: 68.6±7.5yr; PCA: 
68.6±8.7yr). Within the BPH group (Table 4). the average PSA level was 4.9ng/ml. 
with six patients with a serum PSA o f  >4ng/ml. and four patients a PSA o f <4ng/ml. 
No apparent correlation was observed between the levels o f PSA and the levels of 
PSMA. Within the PCA group (Table 5), the average PSMA level in the low stage 
cancer patients (T la  to T2a. n=l 1, 668.8ng/ml) was higher than that in the high stage
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Table 4 Demographics, serum PSA and PSMA levels fo r  BPH
patients
B P H





P S M A
ng/m l
1 68 9 .6 138.25
2 72 5.9 193.8
3 68 4 .7 130.8
4 73 3.4 104.9
5 61 5.2 44 .5
6 54 4 .4 35 .6
7 81 0 .9 136.3
8 71 0 .2 148.3
9 74 0 .6 146.1
10 64 13.7 92 .4
A v er a g e 6 8 .6 4 .9 117.1
R a n g e 54-81 0 .2 -1 3 .7 3 5 .6 -1 9 3 .8
S D 7.5 4 .2 4 8 .7
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1 70 T ic W D 2+2 5.6 9 3 2 .2
2 63 T ic M D 2+2 3 .0 4 5 5 .8
3 72 T ic PD 4+4 7.7 6 3 2 .6
4 6 6 T2a W D 2+3 6 .4 6 8 7 .6
5 64 T2a M D 3+4 2 .6 4 7 1 .0
6 55 T2a M D 2+3 2 .4 9 4 6 .6
7 6 9 T 2a M D 5 9 .0 4 2 3 .8
8 74 T2a M D N R e 5.5 550 .2
9 67 T 2a W D 2+2 5 .6 7 74 .8
10 65 T 2a M D 3+4 7 .9 765 .4
1 1 65 T 2a M D 3+4 7.0 716 .3
12 62 T2b M D 4+5 5 0 .2 6 2 4 .2
13 82 T 2b PD N R 9.3 7 30 .9
14 6 7 T 2b M D 3+3 5.5 349 .5
15 61 T 2b W D 2+2 8.2 6 4 5 .0
16 71 T3 PD 4+4 1230.0 4 1 9 .2
17 93 T3 M D 3+4 4 5 5 .7 4 6 7 .9
Average 6 8 .6 107.2 623.1
Range 55-93 2 .4 -1 2 3 0 3 4 9 .5 -9 4 6 .6
SD 8 .7 309.1 177.7
Low stage (Tla to T2a), 11 patients
Average 6 6 .4 5 .7 6 6 8 .8
Range 5 5 -7 4 2 .4 -7 .9 4 2 3 .8 -9 4 6 .6
SD 5.1 2 .2 181.6
High stage (T2b to T3), 6 patients
Average 7 2 .7 2 9 3 .2 5 3 9 .5f
Range 6 1 -9 3 5 .5 -1 2 3 0 3 4 9 .5 -7 3 0 .9
SD 12.5 4 9 1 .5 148.8
° W D , w ell differentiated; M D , m oderately differentiated; PD , poorly differentiated. 
6 N R , N ot recorded. S core cannot be given due to limited specim en. 
c P = 0 . 16 when com pared to the average P SM A  level in the low  stage cancers.
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cancers (T2b to T3, n=6, 539.5ng/ml); however, this difference was not statistically 
significant (p=0.16, student’s t-test). Collectively these results demonstrate that PSMA 
levels in PCA were significantly higher than those observed for the BPH and the two 
normal male populations.
C. CHARACTERIZATION OF TRANSCRIPTONAL REGULATION OF THE 
PSMA GENE
I. The Effects of EGF and TPA on the PSMA mRNA level in LNCaP cells
EGF and TPA are known to be the inducers of AP-1. In order to determine the role 
of AP-1 proteins in androgen regulated PSMA transcription. LNCaP cells were 
exposed to EGF or TPA and PSMA mRNA levels were examined by Northern blot 
analysis. After treating LNCaP cells with the synthetic androgen R1881 for 48 hrs. the 
PSMA mRNA level was decreased as compared to that in the cells cultured in absence 
o f androgens (Fig. 23). When cells were exposed to 20 or lOOng/ml o f EGF. an 
increase was shown in the PSMA mRNA levels. This induction was suppressed when 
the cells were cultured in the presence o f both EGF and 2nM R1881.
TPA is able to increase A P-1 transactivation via the PK.C signal transduction 
pathway (64). As shown in Fig. 24, PSMA mRNA levels were increased in the 
presence o f 1 nM TPA and decreased in the presence o f 2nM R1881. TPA at 0.1 nM 
did not show a significant induction o f the PSMA mRNA levels. This is possibly 
because the TPA concentration was not sufficient to cause a visible change in the
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Fig. 23. The effects o f androgens and EGF on the PSMA mRNA level in 
LNCaP cells. The cells were cultured in 5% charcoal-stripped FBS medium in 
the absence or presence (+) o f 2nM R1881 and/or EGF (20 or lOOng/ml) for 48 
hours. Fifteen pg o f  total RNA were subjected to electrophoresis followed by 
Northern blot analysis using digoxigenin-labeled PSMA probe (top panel). The 
photograph o f ethidium bromide stained gel (bottom panel) showing the 28S 
(upper band) and 18S (lower band) rRNA confirmed the equal amount and the 
integrity o f the RNA samples.








Fig. 24. The effect o f TPA on the PSMA mRNA level in LNCaP cells. The 
cells were cultured in 5% charcoal-stripped FBS medium in the absence or 
presence (+) o f 2nM R1881 and/or TPA (0.1 or InM) for 48 hours. Fifteen pg 
of total RNA were subjected to electrophoresis followed by Northern blot 
analysis using digoxigenin-labeled PSMA probe (top panel). The same blot 
was probed with 18S rRNA to show the equal loading o f RNA (middle panel). 
The photograph o f the ethidium bromide stained gel (bottom panel) with the 
28S (upper band) and 18S (lower band) rRNA also confirmed the equal 
amount and the integrity o f the RNA samples.
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PSMA mRNA levels by Northern blot analysis. Nonetheless, the increase o f  PSMA 
mRNA levels by EGF and TPA and the inhibition by androgens provided the first 
evidences for the possible involvement o f AP-1 proteins in the regulation o f the 
PSMA gene expression.
2. The Effects of EGF and AP-1 Proteins on the PSMA Promoter Activity
When LNCaP cells are exposed to EGF, various downstream transducers, 
mediators and effectors in the signaling pathway can cause changes at different levels 
including chromosomal remodeling, transcriptional regulation, translational 
regulation, post translational modification and protein stability and turnover. In order 
to analyze the specific effect o f EGF at the level of transcription, the 5' region o f the 
PSMA gene including a 2kb upstream region and the first intron were cloned into the 
luciferase reporter vector. Fig. 4 (page 13 in the Introduction section) illustrates the 
structures o f these luciferase reporter constructs. The promoter and/or enhancer 
activities o f these constructs were examined by transient transfection into LNCaP 
cells. In the first experiment, the constructs' responsiveness to androgens was 
analyzed. As shown in Fig. 25. construct P I . which contains the 0.8kb region 
immediate upstream of the PSMA transcription initiation site, showed about 40-fold 
activation o f the PSMA promoter activity in the absence of androgens. This activity 
was reduced in half in the presence o f 2nM R1881. P2. the construct with a 2kb 
upstream fragment showed the lowest promoter activity and minor suppression by 
androgen. This is probably due to some inhibitory elements that might exist further






















i Stripped + 2nM R1881
basic P1 P2 I/P1 
Luciferase reporter
PSA
Fig. 25. The analysis o f the PSMA promoter and enhancer using luciferase 
assay. The luciferase reporter constructs containing PSMA promoter or the 
first intron (PI,  P2. I/PI) or 5.8kb promoter and enhancer region o f PSA 
(pGL3-/>S^) were transfected in LNCaP cells. The cells were then cultured 
in 5% charcoal-stripped FBS medium in the absence (black bars) or presence 
o f 2nM R1881 (grey bars) for 48 hours and harvested for luciferase assay. 
The luciferase activities were determined as the fold o f induction over the 
transfection o f the pGL2-basic vector (set as 1). The luciferase activity o f 
pGL3-PSA demonstrated the effectiveness of R 1881, a synthetic androgen, 
in causing androgen response.
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upstream o f the 0.8kb fragment. The third construct I/P 1 contains the first intron of the 
PSMA gene that was inserted further upstream of P I . This way the enhancer elements, 
if any, in the first intron could be analyzed. However, instead o f enhancing the activity 
o f PI, I/P 1 showed less promoter activity than PI by itself. The result suggests that the 
first intron could not enhance the promoter activity when being put upstream of the 
promoter, or at least not from this type of artificial orientation. Nonetheless, the 
activity o f I/Pl was also decreased half in the presence o f  2nM R1881. The similar 
suppression o f PI and I/Pl by androgens was probably due to the PI fragment present 
in both PI and I/Pl constructs. A pGL3-PSA luciferase reporter construct carrying a 
5.8kb promoter/enhancer region of the PSA gene was used as the positive control for 
the promoter responsiveness to androgens. Fig. 25 shows that even in the absence of 
androgens the activity o f  PSA promoter was very strong, and as expected, adding 
androgens further induced the PSA promoter to a much higher level. This suggests 
that the R1881 used in the transfection experiments was effective and that androgen 
receptors in LNCaP cells have been functionally activate by R 1881.
Next, the dose effect o f androgens on these PSMA promoter and enhancer 
constructs were analyzed. As shown in Fig. 26, after transient transfection. LNCaP 
cells were cultured in the presence o f 1, 2 or 4 nM R 1881. As the androgen 
concentration increased. PI and I/Pl showed a dose-dependent decrease in the 
promoter activity. The highest promoter activity was found in PI in the stripped 
medium. While P2 exhibited about 10 fold induction in promoter activity, the activity 
did not differ much in the absence or presence of androgens. Since 2 nM R1881 was
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Fig. 26. The effect o f androgens on the PSMA promoter. The PSMA 
luciferase reporter construct P I , P2 or I/PI was transfected in LNCaP cells. 
The cells were then cultured in 5% charcoal-stripped FBS medium in the 
absence (-) or presence o f 1,2 or 4nM R1881 for 48 hours and harvested for 
luciferase assay. The luciferase activities were determined as the fold o f 
induction over the transfection of the pGL2-basic vector (set as 1) and shown 
as the mean +/- SD o f three independent experiments and triplicate 
transfections per experiment.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
73
sufficient to obtain a suppressive effect on the PSMA promoter, this concentration was 
used in the later experiments.
The effect o f EGF on the PSMA promoter and/or enhancer activity was also 
analyzed. LNCaP cells were transiently transfected with PI, P2 or I/Pl followed by 
incubation in the presence o f 2nM 1881 and/or lOOng/ml EGF (Fig. 27). In PI. the 
promoter activity was doubled in the presence of lOOng/ml EGF as compared to the 
transfection in the stripped medium. The addition of R1881 showed a  negative effect 
on the basal (in the stripped medium) or EGF induced PSMA promoter activity. The 
promoter activity was greatly decreased in the presence of 2nM R1881. On the other 
hand, P2 showed little response to either EGF or R1881. Interestingly, l/Pl could only 
respond negatively to androgens, but not to EGF as PI did. suggesting that the 
insertion o f the first intron to the 5' end o f PI might inhibit the induction o f PI by 
EGF.
Since the EGF induced PSMA promoter activity was best observed in PI. this
0.8kb PSMA promoter fragment became the focus in the next experiment to examine 
the direct effect o f AP-1 proteins on PSMA promoter activity. The AP-1 expression 
vectors including c-Jun and c-Fos were cotransfected with PI into LNCaP cells, then 
the cells were incubated in the absence or presence of 2nM R1881 (Fig. 28). 
Cotransfection o f c-Jun or c-Fos resulted in an 8-fold or 7-fold increase in the PI 
promoter activity respectively, as compared to the cotransfectionT^the empty 
expression vector pcDNA and P I . This suggested that c-Jun and c-Fos can 
independently induce the PSMA promoter. Moreover, the simultaneous introduction 
o f c-Jun and c-Fos into LNCaP cells resulted in a 15-fold increase in the PI activity.












Fig. 27. The effect o f EGF on the PSMA promoter. The PSMA luciferase 
reporter construct PI, P2 or I/P! was transfected in LNCaP cells. The cells 
were then cultured in 5% charcoal-stripped FBS medium in the absence or 
presence (+) o f  2nM R1881 and/or lOOng/ml EGF, and harvested for 
luciferase assay 48 hours post transfection. The luciferase activities were 
determined as the fold of induction over the transfection o f the pGL2-basic 
vector (set as 1) and shown as the mean +/- SD o f  three independent 
experiments and triplicate transfections per experiment.
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Fig. 28. The effect o f AP-1 proteins on the PSMA promoter. The AP-1 
expression vectors pcDNA-cJun (cJun), pcDNA-cFos (cFos) or both 
(cJun+cFos) were cotransfected with PSMA luciferase reporter construct PI 
in LNCaP cells. The cells were then cultured in 5% charcoal-stripped FBS 
medium with (+) or without (-) 2nM R1881 for 48 hours and harvested for 
luciferase assay. The luciferase activities were determined as the fold of 
induction over the cotransfection with the empty vector pcDNA3. l/Zeo+ (set 
as 1) and shown as the mean +/- SD o f three independent experiments and 
triplicate transfections per experiment.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
76
When cotransfection was followed by incubation o f LNCaP cells in the presence of 
2nM R 1881, a similar induction pattern by c-Jun, c-Fos or both was observed, but all 
at a suppressed level. This result demonstrated the antagonistic effect o f  androgens on 
the AP-1 induced PSMA promoter activity. Regardless o f the suppression by 
androgens, the data obtained in luciferase assay and Northern blot analysis strongly 
indicated that AP-1 proteins were directly involved in the activation o f PSMA 
promoter.
3. Analysis of the DNA Binding Activity at the AP-1 Sites in the PSMA Promoter 
Region
In order to prove the direct involvement of AP-1 in the transcriptional regulation of 
the PSMA gene, the crucial evidence would be to show the binding o f AP-1 at the 
putative AP-1 sites in the PSMA promoter region. According to the observations in 
the luciferase reporter assays, the PI fragment demonstrated the highest promoter 
activity both in the presence and absence o f androgens. The PI fragment also showed 
the most notable responses to EGF. androgens and the overexpressed A P-1 proteins. 
Thus the three putative AP-1 sites in the PI fragment were of particular interest in 
studying the regulation of the PSMA promoter. Moreover, given the fact that the three 
putative AP-1 sites are located immediately upstream of the PSMA transcription 
initiation site, it is reasonable to believe that these sites are more likely to have an 
important impact on the basic transcriptional machinery. For these reasons, the three
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putative AP-1 sites in the PI fragment were subjected to the detailed DNA binding 
analysis in the following gel shift assays.
The radiolabeled EMSA probes were generated for the three AP-1 sites and the 
flanking sequences. The probes were named PSMA1. PSMA2 and PSMA3 (Fig. 29 
and Table 6). Also generated were a consensus AP-1 probe called PG32-1 and three 
AP-1 like probes: m utl. mut2 and mut3 (Table 6). By using these probes, the 
following gel shift assay experiments were performed to prove the binding o f  AP-1 
proteins at the three putative sites:
DNA Binding Blocked by Consensus AP-1 Nuclear extracts from LNCaP cells 
were incubated with radiolabeled probes including consensus AP-1 (lanes 1 to 3. Fig. 
30). PSMA1 (lanes 4 to 7). PSMA2 (lanes 8 to 11) and PSMA3 (lanes 12 to 15). A 
protein complex was formed on the consensus AP-1 site (lane 2). and a complex of 
similar size was also formed on the three putative AP-1 sites in PSMA promoter (lanes 
5 .9  and 13; the upper shift with the large arrow). Another smaller protein complex 
was formed on the PSMA2 and PSMA3 sites (lanes 9 and 13; the lower shift with the 
small arrow), probably representing a protein complex formed by different AP-1 
family members. The upper shift was consistently observed in all experiments, 
whereas the lower shift varied among some of the experiments. Nonetheless, the 
formation o f both protein complexes on the PSMA AP-1 sites was inhibited by 
preincubation o f the cold consensus AP-1 probes with LNCaP nuclear extracts (lanes 
7, 11 and 15). The competition o f DNA binding between the consensus AP-1 probe 
and PSMA probes provided the first evidence for the specificity o f AP-1 binding at the 
three PSMA AP-1 sites.
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PI (1791-2522) Intron I (2876-4973)
P2 (588-2522)
PSMA 5 ’ nts 588-4973 Q AP-1 sites
Fig. 29. The three AP-1 sites in the close vicinity o f the PSMA 
transcription initiation site. The EMSA probes that contain these three AP- 
1 sites and the flanking sequences were named PSMA I, PSMA2 and 
PSMA3 respectively. The numbers represent the number o f  the nucleotides 
in the PSMA genomic sequence (Genbank accession number AF007544). 
The shaded ovals represent the AP-1 sites. The arrow stands for the 
transcription initiation site (nt 2488) o f the PSMA gene.
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Table 6 EMSA probes with AP-I sites used in this study
Name of the Probe Feature AP-1 site
P M S A I 1964-1997" TGcCTCA
P S M A 2 2 3 0 9 -2 3 4 2 TTAtTCA
P S M A 3 2 3 5 0 -2 3 8 3 TTAtTCA
A P-1 PG 32-1* TGAGTCA
r PG 32 mut 1 TGgGTCA
A P -I like" ■< PG 32 mut 2 TGcGTCA
I PG 32 mut 3 TGtGTCA
a The num bers represent the beginning and the end nucleotides in AP-1 sites 
according to  their positions in PSM A  genom ic sequence (G enebank accession  
number A F 0 0 7 5 4 4 ).
* P G 32-I is a 4 8 -b p  ds o ligon u cleotide containing a con sensu s AP-1 site  in the 
center and flanked w ith artificia lly  designed nucleotides (a g ift from  Dr. T . B os at 
E V M S).
‘ The sq u en ce o f  AP-1 like probes are the sam e as P G 32-I excep t for the single  
change at the third nucleotide in the concensus AP-1 site.
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Fig. 30. Inhibition o f DNA-binding activity by AP-I probe. The LNCaP 
cells were cultured in 5% FBS medium for 48 hours. The nuclear extracts 
{LNCaP N. E.) were prepared and used in EMSA. The following 
radiolabeled probes were used: AP-l {lanes I to 3), PSMA 1 {lanes 4 to 7). 
PSMA 2 {lanes 8 to 11), and PSMA 3 {lanes 12 to 15). In competition 
assays, cold probes were preincubated with the nuclear extracts prior to the 
addition o f  the labeled probes. The arrows indicate two different complexes 
formed on the probes.
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DNA Binding Blocked by AP-1 Like Probes The consensus A P-1 site contains 
seven base pairs: TGAGTCA. When a single nucleotide change was introduced at the 
third nucleotide in the consensus AP-1 site, the new sites were called m u tl, mut2 and 
mut3 (Table 6). Despite the single nucleotide change, the mutants still keep the DNA 
binding activity similar to the consensus AP-1 site when incubated with LNCaP 
nuclear extracts (lanes 2, 4, 6 and 8. Fig. 31 A). Thus the mutants were called ‘AP-1 
like sites' and used as the cold probe in the competition experiments with the PSMA 
AP-1 sites. When the cold AP-1 like probes were preincubated with LNCaP nuclear 
extracts, the DNA binding activities on the PSMA1, PSMA2 and PSMA3 sites were 
partially inhibited (lanes 4, 5 and 6. Fig. 31B, C and D). Preincubation with a 
nonspecific oligonucleotide from CMV genome did not affect the DNA binding at all 
(lane 7. Fig. 3 IB. C and D). The inhibition by AP-1 like probes provided further 
evidence for the binding o f AP-1 proteins at the three PSMA AP-1 sites.
DNA Binding Inhibited by AP-1 Specific Antibodies In order to demonstrate that
AP-1 proteins were in the complexes formed on the three PSMA AP-1 sites, AP-1 
specific antibodies were used in the preincubation with the LNCaP nuclear extracts 
before the addition of the radiolabeled PSMA AP-1 probes. As shown in Fig. 32, both 
c-Jun and c-Fos specific antibodies were able to block the formation o f the protein 
complexes on the three PSMA AP-1 sites (lanes 3 .4 , 8. 9, 13 and 14, Fig. 32), 
whereas nonspecific rabbit IgG did not affect the DNA binding activity at all (lanes 5. 
10 and 15). Moreover, both the upper shift (large arrow) and lower shift (small arrow) 
were inhibited. The competition by c-Jun and c-Fos specific antibodies suggested that 
AP-1 proteins were indeed in the protein complexes formed on the three AP-1 sites,
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A. LNCaP N.E.: - + - + - + - +
1 2 3 4 5 6 7 8
Probe: AP-1 mutl mut2 mut3
Fig. 31. Inhibition o f DNA-binding activity by AP-1 like probes. The 
LNCaP cells were cultured in 5% FBS medium for 48 hours. The nuclear 
extracts (LNCaP N. E.) were prepared and used in EMSA. The following 
radiolabeled probes were used: AP-1, mut-1, mut-2 and mut-3 (A); PSMA 1 
(B); PSMA 2 (C); PSMA 3 (D). In competition assays (panels B, C  and D), 
cold probes PSMA I, PSMA 2, PSMA 3, mut-I, mut-2, mut-3 or irrelevant 
oligonucleotides from CMV gene (CMV oligo) were preincubated with the 
nuclear extracts prior to the addition of the labeled probes. The arrows 
indicate two different complexes formed on the probes.
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PSMA1 PSMA 2 PSMA 3
Fig. 32. Inhibition o f DNA-binding activity by AP-1 antibodies. The 
LNCaP cells were cultured in 5% FBS medium for 48 hours. The nuclear 
extracts (LNCaP N. E.) were prepared and used in EMSA with the 
radiolabeled PSMA 1 (lanes I to 5), PSMA2 (lanes 6 to 10) or PSMA3 
(lanes 11 to 15) as probes. For antibody competition assays, rabbit 
polyclonal antibody specific to cJun (acJnri) or cFos (acFos) or nonspecific 
rabbit IgG (IgG) was incubated with the nuclear extracts prior to the 
addition o f the labeled probe. The arrows indicate two different complexes 
formed on the probes.
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and that the interactions between the antibodies and these AP-1 proteins interfered 
with their DNA binding activities.
The Binding o f  In Vitro Translated AP-l Proteins Beside the above three 
competition experiments, a direct approach to prove the binding o f AP-1 proteins at 
the PSMA AP-1 sites was to use purified AP-1 proteins in the incubation with the 
radiolabeled probes. AP-1 proteins including c-Jun and c-Fos were generated by in 
vitro translation in rabbit reticulocyte lysate system (kindly provided by Dr. T. Bos. 
EVMS). Equal amount o f translated products were mixed to allow the formation of 
AP-1 dimers. The mixture was then added to the incubation with the PSMA AP-1 
probes. As shown in Fig. 33, in vitro translated AP-1 proteins were able to form 
complexes on all three PSMA AP-1 sites (lanes 2. 5 and 8. large arrow). Other 
complexes were observed only in the LNCaP nuclear extracts (small arrow), probably 
because o f a variety of AP-1 proteins present in the LNCaP nuclear extracts versus the 
single type o f AP-1 dimer in the in vitro translated product. The size o f in vitro AP-1 
complex was similar to the upper shift observed in LNCaP nuclear extracts, suggesting 
that the upper shift in the LNCaP nuclear extracts is likely to be the dimer o f c-Jun and 
c-Fos.
Taken together, the data from the above four experiments suggested that AP-1 
proteins are the proteins that bind to the PSMA AP-1 sites.
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Mock translation: 
In  v itro  AP-1 : 
LNCaP N.E.: +
Probe: PSMA 1 PSMA 2 PSMA 3
Fig. 33. The DNA-binding activity o f in vitro translated AP-1. The LNCaP 
cells were cultured in 5% FBS medium for 48 hours. The nuclear extracts 
{LNCaP N. E.) were prepared and used in EMSA. In vitro AP-I was the 
mixture o f equal amount o f in vitro translated c-Jun and c-Fos proteins from 
rabbit reticulocyte lysates. Product from the translation reaction without the 
input o f c-Jun or c-Fos mRNA was used as negative control {mock 
translation). The following radiolabeled probes were used: PSMA 1 {lanes I 
to 3), PSMA 2 {lanes 4 to <5), PSMA 3 {lanes 7 to 9). The large arrow 
indicates the shift shared by the LNCaP nuclear extracts and in vitro AP-1. 
The small arrow  indicates the complexes formed only with LNCaP nuclear 
extract.
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4. Examine the Effects o f Androgens and EGF on the DNA Binding at the AP-1 
Sites
After the binding o f AP-1 at the three putative AP-1 sites was made clear, the next 
logical question was if androgens and EGF have an impact on the AP-1 binding 
activities and how such an impact may relate to the downregulation of PSMA 
transcription by androgens and the upregulation of PSMA transcription by EGF. To 
answer this question, the effect o f androgens and EGF on the AP-1 binding at the 
PSMA sites was examined in the following experiments:
Effect o f  Androgens on AP-1 Binding LNCaP cells were cultured in the absence 
o f androgens, or in the presence o f 1. 2 or 4 nM R 1881. Nuclear extracts were 
prepared and used in the incubation with three radiolabeled PSMA AP-1 probes. As 
shown in Fig. 34. the maximum AP-1 binding was observed in the absence of 
androgens (lane 1 in panels A. B and C). As R 1881 concentration increased, the AP-1 
binding at all three sites was decreased (lanes 2 to 4). Both the upper shift (large 
arrow) and lower shift (small arrow) were decreased at the PSMA1 and PSMA2 sites 
(panels A and B). whereas at the PSMA3 site, only the upper shift (large arrow in 
panel C) was inhibited while the lower shift (small arrow in panel C) was virtually not 
affected by androgens. Moreover, when R1881 was added to the nuclear extracts 
prepared from LNCaP cells cultured in the absence o f androgens, AP-1 binding 
activity was inhibited. On the other hand, when ethanol -the solvent for R 1881- was 
added to the same nuclear extracts, the AP-1 binding was unaffected (lane 5 versus 
lane 6 in panels A. B and C). Taken together, the results suggested that androgens can 
inhibit the AP-1 binding at the three PSMA sites.


















Added to assay  R V R V R V
R1881 (nM) 1 2 4 1 2 4 1 2 4
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Fig. 34. Inhibition o f AP-1 DNA-binding activity by androgens. The LNCaP cells were cultured in 5% charcoal- 
stripped FBS medium in the absence or presence o f 1,2 or 4 nM R1881 for 48 hours. The nuclear extracts were prepared 
and used in EMSA with the radiolabeled PSMA 1 (A), PSMA 2 (B) or PSMA 3 (C) as probes. EMSA was also performed 
by adding 2nM R1881 (R) or the same amount o f vehicle (I7) to the incubation with the nuclear extracts isolated from 




The Effect o f  EGF on AP-1 Binding Similar to the approach used to study the 
effect o f androgens, LNCaP cells were also cultured in the stripped medium in the 
presence or absence of R 1881 and/or EGF. Nuclear extracts were prepared and used in 
the EMSA with the three PSMA AP-1 probes (Fig. 35). At all three sites (Fig. 35A. B 
and C), the AP-1 binding was increased in the absence o f androgens as compared to in 
the presence o f androgen (lane 2 versus lanes 1 and 3: lane 5 versus lane 6). Moreover, 
the AP-1 binding was increased by EGF. especially at a higher concentration (lane 2 
versus lanes 4 and 5). This increase was also shown in the presence o f androgens (lane 
3 versus lane 6). The EGF induced AP-1 binding was slightly suppressed by 
androgens (lane 5 versus lane 6). At all three sites, the formation o f the large protein 
complex (large arrow) was affected by EGF and androgens, whereas at the PSMA3 
sites, the small protein complex (small arrow in Fig. 35C) remained virtually 
unaffected. This suggests that the AP-1 protein components in the complexes were 
different at the three sites, with some complexes more sensitive to the changes in 
androgens and EGF than the others and other present more consistently. Cold probes 
containing the three PSMA AP-1 sites or the consensus AP-1 site were included in the 
competition experiments run in parallel to show the specificity o f the AP-1 binding 
(lanes 7 and 8). The results indicated that EGF could induce the AP-1 binding and 
androgen was able to act in an antagonistic manner to inhibit the EGF induced A P-1 
binding.
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Fig. 35. Increased AP-1 DNA-binding activity with EGF. The LNCaP cells 
were cultured for 48 hours in 5% charcoal-stripped FBS medium in the 
presence or absence o f 2nM R1881 and/or EGF (20 or lOOng/ml) (lanes 1 to 
6) or 5% FBS medium (lanes 7 and 8). The nuclear extracts were prepared 
and used in EMSA. The following radiolabeled probes were used: PSMA 1 
(A), PSMA 2 (B ), and PSMA 3 (C). The specificity o f AP-1 binding was 
shown in competition assays where the cold probe (PSMA I, PSMA 2, PSMA 
3 or AP-1) was preincubated with the nuclear extracts prior to the addition 
o f the labeled probe. The arrows indicate two different complexes formed 
on the probes.
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S. Probe the Interaction between the AP-1 Proteins and Androgen Receptors
Previous studies have shown the interaction between the AP-1 transcription factor 
family members and androgen receptors had mutual effect on both o f their DNA 
binding and transactivation abilities (56,57). For instance, the induction o f PSA gene 
by androgens was suppressed by the interaction between androgen receptor and AP-1 
family members (56). suggesting an antagonistic effect between AP-1 and androgen 
receptor. Therefore it is possible that by a similar antagonistic effect, androgens might 
interfere with the AP-1 binding to the putative AP-1 sites in the PSMA promoter, and 
indirectly represses the transcription o f PSMA. Based on this rationale and the data 
observed in the above experiments, a model was proposed to explain the androgenic 
inhibition o f AP-1 DNA binding at the PSMA AP-1 sites and the induction o f AP-1 
binding in the absence of androgen (Fig. 36). In the absence of androgen, androgen 
receptors (AR) are inactivated and do not interact with AP-1 family members, so the 
AP-1 family members are free to bind to the putative sites in PSMA promoter and 
induce the transcription. On the other hand, when androgen is present, androgen 
receptors are activated and can interact with AP-1. The interaction can either interfere 
with the binding o f AP-1 to the sites in PSMA promoter or inhibit the interaction of 
the AP-1 complexes with the nearby basic transcriptional machinery. Either way. the 
result can lead to the suppression of PSMA transcription.
Since in a previous study, the interactions between AR and AP-1 in LNCaP cells 
have been demonstrated by co-immunoprecipitation (56), the focus here was to 
demonstrate the interaction between AR and AP-1 in the protein complexes formed at 
the three putative AP-1 sites in the PSMA promoter.
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In the p resence of androgen V
c-Jun (  c-Fosor
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Fig. 36. Proposed mechanism for the regulation of the PSMA 
gene transcription by AP-1 and androgens. Note that the AR in 
blank square stands for the inactivated AR in the absence o f  
androgen. In the presence o f  androgen (triangle), AR is activated 
(dotted square). The size o f the arrow indicates the level o f  the 
gene transcription.
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Inhibition o f  AP-1 Binding by AR Antibody In order to examine if AR is involved 
in the AP-1 complexes, an antibody specific to AR was used in the incubation with the 
radiolabeled PSMA AP-1 probes and LNCaP nuclear extracts (Fig. 37). When the AR 
antibody was added to the preincubation with LNCaP nuclear extracts before adding 
the radiolabeled probes, the formation o f the AP-l protein complexes was inhibited at 
all three AP-1 binding sites (large arrow, lanes 1. 5 and 9 versus lanes 3. 7 and 11). On 
the other hand, when the AR antibody was added after the radiolabeled probes, there 
was no inhibition o f the AP-1 protein complexes at the AP-1 sites (large arrow in lanes 
4, 8 and 12). Nonspecific rabbit IgG did not show any inhibitory effect on the AP-1 
complexes (lanes 2. 6 and 10). The binding of AR at its own ARE site was inhibited 
by the AR antibody, but not by rabbit IgG. confirming the specificity o f the AR 
antibody in recognition o f AR (lanes 13, 14 and 15). The inhibition by AR antibody 
suggests that AR is involved in the AP-1 complex formed at the PSMA AP-1 sites.
The recognition site for AR antibody appeared to interfere with the DNA binding of 
the complex, therefore the interaction between AR and its antibody blocked the 
AR/AP-1 complex from binding to the PSMA AP-1 sites. For the same reason, if the 
antibody was added after the AR/AP-1 complexes were formed at the AP-1 sites, the 
recognition site for the antibody was blocked and no inhibition was shown.
Inhibition o f  AP-1 Binding by ARE  Androgen responsive element (ARE) is the 
consensus DNA element to which the activated AR can bind. To further investigate 
the interaction between AR and AP-1, cold ARE probe was used as a competitor in 
EMSA experiment (Fig. 38). When preincubated with LNCaP nuclear extracts before 
the radiolabeled PSMA AP-1 probes were added, cold ARE probe was able to
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Fig. 37. Inhibition of AP-1 DNA-binding activity by androgen receptor 
antibody. The LNCaP cells were cultured in 5% FBS medium for 48 hours. 
The nuclear extracts were prepared and used in EMSA with the radiolabeled 
PSMA 1 (lanes 1 to 4), PSMA2 (lanes 5 to 8), PSMA3 (lanes 9 to 12) or ARE 
{lanes 13 to 15) as probe. For antibody competition assays, rabbit polyclonal 
antibody specific to androgen receptor (aAR) was incubated with nuclear 
extract prior to (pre-) or after (post-) the addition o f the labeled probe. 
Nonspecific rabbit IgG (rabbit IgG) was used as the negative control and 
added in the preincubation before the addition of the labeled probe. The large 
arrow  indicates the shift competed by AR antibody. The small arrows 
indicate other putative AP-1 complexes formed on the probes.
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Fig. 38. Inhibition o f AP-1 DNA-binding activity by androgen responsive 
element probe. The LNCaP cells were cultured in 5% FBS medium for 48 
hours. The nuclear extracts were prepared and used in EMSA with the 
following radiolabeled probes: PSMA 1 (lanes I to 5), PSMA 2 (lanes 6 to 10), 
PSMA 3 (lanes 11 to 15) and ARE (lanes 16 to 19). In competition assays, cold 
probes (PSMA 1, PSMA 2, PSMA 3, ARE, mutant ARE or irrelevant 
oligonucleotides from CMV gene) were preincubated with the nuclear extracts 
prior to the addition o f the labeled probe. The large arrow indicates the shift 
competed by ARE. The small arrows indicate other putative AP-1 complexes 
that might also be affected by ARE.







compete the binding o f AP-1 complexes to all three PSMA AP-1 sites (lanes 3, 8 and 
13 versus lanes 1,6 and 11). On the other hand, cold mutant ARE (mARE) probe or 
nonspecific oligonucleotides from CMV genome (CMV oligo) did not have 
competitory effect on the AP-1 complex formation (lanes 4, 5. 9, 10, 14 and 15). 
Moreover, cold ARE also competed the AR binding at ARE (lane 16 versus lane 17). 
whereas the competition was absent with cold mARE or CMV oligo (lanes 18 and 19). 
All these experiments confirmed the specific competition o f AP-1 binding by ARE. 
Besides the inhibition o f the large AP-1 complex (large arrow), the small complexes 
(small arrows) were also competed by ARE (small arrows in lanes 3 and 13). Along 
with the previous experiment, the inhibition by ARE and AR antibody strongly 
suggested the presence o f A R in the AP-1 complex formed at the PSMA AP-1 sites.
Comparison o f  AP-I DNA Binding in LNCaP and PC-3 Cells To further confirm 
that it was AR - not the other factors - that interact with AP-1 in the protein 
complexes, the AP-1 binding activity was compared between LNCaP - an AR 
expressing cell line and PC-3 - a prostate cancer cell line that does not express AR 
(65). As shown in Fig. 39, when the nuclear extracts from LNCaP (L) were incubated 
with the radiolabeled PSMA AP-1 probes, strong DNA binding activities were 
detected at all three sites (lanes 1, 5. and 9). On the other hand, when the nuclear 
extracts from PC-3 (P) were used in EMSA, little AP-1 binding activities were 
detected at the three sites (lanes 2, 6 and 10). Although the protein complex formation 
was competed by cold PSMA AP-1 probes (lanes 3, 7 and 11), cold ARE probe did 
not have any competitory effect on these protein complexes (lanes 4, 8 and 12). The 
result suggested that when PC-3 derived nuclear extracts were used, much less AP-1
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Fig. 39. Comparison o f  the AP-1 DNA-binding activity in LNCaP and PC-3 
cells. The LNCaP cells (L) were cultured in 5% FBS medium and PC-3 cells 
(P) were cultured in 10% FBS medium. The nuclear extracts (N. E.) were 
prepared after 48 hours and used in EMSA with the following radiolabeled 
probes: PSMA 1 {lanes 1 to 4), PSMA 2 (lanes 5 to 8), PSMA 3 (lanes 9 to 12). 
In competition assays, cold probes {PSMA I, PSMA 2, PSMA 3 o r ARE) were 
preincubated with the nuclear extracts from PC-3 cells prior to the addition of 
the labeled probe. The large arrow  indicates the common AP-1 complex in two 
cell lines. The small arrows indicate other putative AP-1 complexes present in 
LNCaP cells.
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protein complexes were formed on the three PSMA AP-1 sites as compared to the 
LNCaP nuclear extracts. This is understandable because PSMA was found to be 
expressed only in LNCaP cells, but not in PC-3 cells (13). Moreover. PC-3 cells do 
not express AR; therefore AR was not involved in these protein complexes in PC-3 
cells. Therefore the inhibition o f AP-1 DNA binding on the PSMA AP-1 sites by ARE 
was specific to the AR expressing cells.




A. GENERATION OF RECOMBINANT PSMA
1. Technical Concerns
The successful expression and purification o f recombinant PSMA in the
baculovirus/insect cell system was accomplished in this study. Full length PSMA 
cDNA was constructed into a 6xHistidine-tag containing expression vector to generate 
the recombinant virus and the recombinant PSMA was expressed in virus-infected 
insect cells. Since PSMA is known as a transmembrane protein (12), the following 
five problems were circumvented in establishing the rPSMA expression and 
purification procedures:
First, the insect cell lines vary in terms of their virus replication efficiency and 
foreign protein productivity (66). For example, not all insect cell lines express 
transmembrane proteins at the same level. Therefore, both the Sfi) and Hi5 insect cells 
were tested in order to obtain a high level expression o f rPSMA. While Sf9. the first 
insect host evaluated, was capable o f accommodating virus replication and generating 
high titer rPSMA virus stock, its rPSMA transcription and translation efficiency was 
somehow low compared to that o f Hi5 cells. Thus the Hi5 insect cell line was chosen 
as the host for the large-scale rPSMA expression experiments.
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Second, the original serum-supplemented medium was replaced with serum-free 
medium. Having no obvious influence on the Hi5 cell growth and rPSMA expression 
efficiency, this modification has eliminated the possible contamination of serum 
proteins, making the purification process easier.
Third, the rPSMA expression level was also compared in the suspension versus 
monolayer cell cultures, with a higher level o f rPSMA expression obtained in the 
monolayer culture. This difference was not surprising considering some o f the 
unfavorable factors in the suspension culture, such as shear stress that might affect the 
expression o f glycoproteins destined to be presented on the cell surface (66).
Fourth, unlike other secretory proteins that can be easily purified from culture 
supernatant, protein solubilization is a major concern especially when purifying a 
transmembrane glycoprotein. In the case o f  native PSMA, detergents such as SDS and 
Triton-X were required to solubilize and purify PSMA from LNCaP cells (14). 
However, because Triton-X would interfere with the binding o f  the histidine tag in the 
rPSMA to the metal chelating affinity resin, another detergent called Igepal was 
applied together with SDS to solubilize the rPSMA in insect cells.
Fifth, two different metal chelating affinity resins have been compared for the 
rPSMA purification efficiency. Because the Nickel affinity resin was found to bind 
non-specific proteins more than the Cobalt affinity resin, the Cobalt affinity resin was 
selected to purify the rPSMA.
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2. Characteristics o f rPSMA
Western blot analyses indicated that the rPSMA consisted o f two molecular 
species, a lOOkDa and 200kDa protein. These molecular species agreed with the 
molecular weight observed previously for native PSMA (14). Furthermore, rPSMA 
was shown to react with multiple MoAbs specific for PSMA including 7E11, which 
recognizes the first 6 amino acids o f the amino terminus located at the inner surface o f 
the cell membrane (15), and J591 which binds to the extracellular domain (20). These 
results strongly suggest that the baculovirus rPSMA mimics the native PSMA with 
respect to protein conformation and immunoreactivity. This observation is supported 
by a recent paper by Lodge et al. who described the generation o f a rPSMA in a 
baculovirus expression system and showed that PSMA specific T cells could be 
induced in vitro when antigen presenting cells were pulsed with rPSMA. These 
experiments demonstrated that the rPSMA was immunologically recognized similar to 
the native PSMA (67).
Although the native and recombinant PSMA did not show apparent differences in 
molecular weight, their glycosylation profiles were different. The glycans present on 
rPSMA were primarily N-Iinked high mannose type, with a small amount o f the 
complex type. On the contrary, the high mannose type N-glycans were rare in LNCaP 
derived native PSMA, with the complex type N-glycans being the major glycans (16). 
Thus the glycosylation analysis suggests that there might be two subpopulations o f N- 
glycans in the PSMA glycoprotein molecule, and that there might be significant 
differences in terms o f the amount and ratios of these N-glycans present in the native 
and rPSMA. Although the differences in glycosylation between the native and
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baculovirus recombinant proteins have been reported previously (66), it is unclear 
what caused the production o f the high mannose type N-glycans in the rPSMA when 
compared to the native PSMA. A possible explanation is that different insect cell lines 
might have different capacities to process N-glycans; some are unable to fully process 
N-glycans from the high mannose type to the complex type (66,68). For example, a 
previous study on the N-glycosylation pathway in baculovirus-infected insect cells 
showed that the N-glycans on gp64, a major structural glycoprotein in AcMNPV were 
unable to be processed to the complex type (69). The variable patterns in glycosylation 
might also explain the two closely migrating lOOkDa rPSMA species observed on 
SDS-PAGE, even though their differences in size were so little that by mass 
spectrometry they were detected as a single but relatively broad lOlkDa peak. 
Nonetheless, the complexity o f glycosylation did not appear to affect the 
immunoreactivity o f the rPSMA.
N-glycans in LNCaP derived PSMA were found to be mainly of the complex 
type. This observation is not in agreement with a previous study by Holmes et al. who 
reported that the N-glycans on LNCaP derived PSMA are the endo H sensitive high 
mannose type, and that this might result from a possible defect in the glycosylation 
pathway in LNCaP cells (16). However, it is notable that in Holmes' study (16) only a 
small amount o f PSMA in the LNCaP cell lysates was hydrolyzed by endo H. whereas 
the majority o f PSMA remained intact as the 1 OOkDa species. This suggests that in 
contrast to their conclusion, the majority o f  the N-glycans on LNCaP derived PSMA 
were actually endo H resistant, and thus are the complex type. The partial 
deglycosylation of PSMA by endo H observed in Holmes’ study (16) might be due to
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the different LNCaP cell extracts used for the glycosidase experiments: whole cell 
lysates were used by Holmes, in contrast to the membrane extracts used in our study. 
Whole cell lysates are likely to contain various premature proteins resulting from 
different steps in the post-translational modification cascade, while most glycoproteins 
present on cell membranes and secretory proteins are o f the mature complex type 
glycans. This could explain why the N-glycans on native PSMA were shown to be o f 
the high-mannose type or multiple glycosylated forms in Holmes’ study, compared to 
the complex type found in the present study. This consideration was actually proven in 
the Holmes study (16) based on their observation that the N-glycans on PSMA in 
prostate cancer patient’s serum (i.e. a secreted form o f PSMA) were exclusively o f the 
complex type. Another possible explanation is the difference in cell culture and 
passage. If the LNCaP cells were not synchronized in culture, it could generate artifact 
products during glycosidase digestion. Overall it seems more persuasive that a defect 
in the glycosylation pathway is unlikely to exist in LNCaP cells, so that the N-glycans 
on PSMA can be processed to the complex type.
Recombinant PSMA will have many potential applications in clinical and basic 
science research for prostate cancer. For example, rPSMA can be applied as 1) a 
standard reference for the development o f serodiagnostic assays: 2) an antigen 
substitute in phage display library screening and for PSMA specific recombinant 
MoAb generation; 3) a pharmaceutical material in preparing therapeutic strategies, 
such as the introduction of immunocompetent T cell or dendritic cell based immune 
responses; or 4) a vaccine for prostate cancer prevention or treatment.
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The successful production and purification o f a full length glycosylated rPSMA 
protein will provide a renewable source o f this unique prostate cancer-associated 
antigen, and promote the study and application o f this potential tumor biomarker for 
the diagnosis, prognosis and therapy o f prostate cancer.
B. PSMA SELDI IMMUNOASSAY
One o f the purposes o f this study was to develop a quantitative immunoassay to 
measure PSMA in serum. Prior to this study, the only successful way to detect PSMA 
in body fluids was by Western blotting, an approach that is useful for preclinical 
research, but not easily converted to a reliable quantitative clinical assay (26,27.53).
By using the purified rPSMA, a quantitative PSMA immunoassay using the innovative 
ProteinChip® SELDI-MS technology was successfully developed. The concept and 
potential application o f  the mass spectrometry immunoassay has been described in a 
number o f previous studies (59,70,71). In this report, the ProteinChip® array was used 
as the assay platform. The PSMA protein was captured on the antibody-coated 
preactivated array. This was followed by mass spectrometry to detect and quantitate 
the antigen. The initial results, described herein, demonstrated that the lOlkDa PSMA 
was correctly identified by its mass and could readily be quantitated in serum.
Based on these results, a group study was further conducted to quantitate PSMA 
in serum from normal male donors and patients diagnosed with BPH, PCA and 
prostatitis. The ability o f  PSMA as a potential biomarker o f disease progression was 
assessed. The highest PSMA levels were found in sera from patients with prostate
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cancer, and the PSMA values also differed significantly from the normal and benign 
groups. These results confirmed a similar trend of difference among the normal, BPH 
and PCA samples observed by Western blot analysis in our previous study (27), and 
therefore validate the sensitivity, specificity and feasibility o f SELDI ProteinChip® 
technology as an immunoassay format for measuring serum PSMA.
Most noteworthy was the observation that PSMA levels significantly discriminated 
BPH from the PCA samples that had PSA values between 4-10ng/ml. PSA has been 
considered the standard tumor biomarker for prostate cancer diagnosis, but its clinical 
utility is hampered by the sensitivity and specificity issues that have been raised by 
many investigators (4.7). When a PSA cutoff o f 4ng/ml is used as the parameter for 
diagnosis, a substantial overlap will be present between BPH and PCA (4). For 
instance, approximately 25% o f patients who are diagnosed with PCA have a PSA 
value less than 4ng/ml (72), whereas an equal percent of BPH patients have PSA 
>4ng/ml. Therefore the sensitivity and specificity o f a cutoff at 4ng/ml is problematic. 
If the PSA cutoff for recommending a prostate biopsy is lowered to improve 
sensitivity, it will trigger a significant number o f additional and unnecessary biopsies 
(73). Free to total PSA ratio or percentage o f free PSA has been employed to improve 
the operating characteristics, however 5-10% o f PCA still remained undetected (4.7). 
Using the SELDI PSMA immunoassay described in this study, all samples with a PSA 
between 4-10ng/ml were correctly “diagnosed” as either BPH or PCA. It is in this 
context that serum PSMA will be o f most interest for clinical application, because the 
observation suggests that PSMA may be a clinically valuable biomarker, either used
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
108
alone or in combination with PSA, for the early and accurate diagnosis o f PCA, i.e. 
discriminating BPH and PCA.
Despite the success in the differentiation of BPH and PCA, the serum PSMA levels 
were not able to distinguish low stage from high stage prostate cancers, or Gleason 
grades less than 6 from 7-10. Nonetheless, due to the small sample size, this 
observation is still inconclusive and certainly requires further studies with larger 
numbers of samples to evaluate correlations with grade and stage, and the prognostic 
utility o f serum PSMA.
This is the first report describing, not only the quantitation o f PSMA in serum, but 
the use o f an unconventional immunoassay format. One o f the major differences from 
the conventional immunoassay platforms is that SELDI requires only small quantities 
o f primary antibody and does not need a second PSMA antibody or labels as required 
for ELISA and other similar immunoassay formats to detect and quantitate antigens. 
For this reason, the conventional assays usually detect antigen indirectly based on the 
colorimetric or fluorometric changes in solution, whereas SELDI immunoassay can 
quantitate antigen directly according to the mass signal. This enables SELDI to bypass 
the problem of cross reactivity o f antibody with other molecules similar to the specific 
antigen, while the same problem has been shown to affect the performance of 
conventional assays and led to the overestimation of antigen. PSMA SELDI 
immunoassay described in this study was based on the first generation MoAb 7E11. 
Although five PSMA specific antibodies have been tested herein, more PSMA 
antibodies that recognize either the intracellular or extracellular domains o f the PSMA
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glycoprotein should also be evaluated in the future to assess if these antibodies can 
further enhance the assay sensitivity.
Another advantage of the SELDI ProteinChip® immunoassay system is that 
multiple biomarkers can be measured simultaneously in a multiplex format. In a 
previous study, we described the successful measurement o f both PSMA and PSA 
(both the free- and antichymotrypsin complexed PSA) in seminal plasma and sera 
(59). The multiplex format would have a major benefit as it could simultaneously 
measure a combination o f PSMA with the various PSA forms that have proven to have 
an advantage over PSMA or PSA alone in discriminating BPH from PCA. Therefore 
plans will be made in the future study to extend the SELDI immunoassay to a 
multiplex version.
C. REGULATION OF THE PSMA TRANSCRIPTION BY AP-1
1. Androgen Independent Expression of PSMA
Previous studies have shown that the expression of PSMA was downregulated in 
the presence o f androgen and upregulated after androgen deprivation therapy (19,22- 
24). While the expression o f prostate tissue related genes such as PSA and human 
glandular kallikrein (hK2) is normally induced by androgens (74-79), androgen 
independent gene expression was not unseen (80,81). The development o f prostate 
organ and the progression o f  prostate cancer are androgen dependent initially, but very 
often, prostate cancer cells become androgen independent during tumor progression
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
110
and metastasis. Growth factors and cytokines such as EGF, IGF and IL-6 were shown 
to be involved in the gene regulation in the androgen independent stages (82-86). As 
observed in this study, the increased transcription of PSMA gene when LNCaP cells 
were cultured with EGF - especially when androgens were absent in the medium - 
suggested that EGF is a growth factor responsible for the androgen independent 
expression o f PSMA. EGF exerts action through binding to the corresponding EGF 
receptors on the cell membrane and initiates an intracellular phosphorylation cascade, 
leading to the activation o f mitogen-activated protein kinases (MAPKs), 
p42/extracellular signal-regulated kinase (ERK)2, which is a key kinase in mediation 
o f growth factor-induced mitogenesis in prostate cancer cells. This cascade can finally 
lead to the recruitment o f transcription factors such as AP-1 (87).
2. The Binding of AP-1 at the PSMA Promoter Region
The sequence analysis in the 5’ region of the PSMA gene revealed 14 putative AP- 
1 binding sites. EMSA examined the DNA binding at three o f  the AP-1 sites in the 
close vicinity o f the PSMA transcription initiation site. The results showed that AP-1 
transcription factors are indeed bound to these sites. The specificity o f the binding was 
confirmed by the competition of the consensus AP-1 or AP-1 like binding sites, the 
inhibition by the c-Jun and c-Fos specific antibodies and the binding o f  in vitro 
translated AP-1 proteins. AP-1 is a transcription factor family members consist of 
homodimers and heterodimers o f Jun, Fos, or activating transcription factor (88-90). 
The stability o f these homo- and heterodimers varies among the different members.
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The several protein complexes observed at the three PSMA A P-1 sites were probably 
due to the formation o f different dimers among the AP-1 family members. The most 
frequently observed complex was the large complex, which was with the same size as 
the complex formed by the in vitro translated c-Jun and c-Fos and was competed by c- 
Jun and c-Fos specific antibodies. For this reason, this large complex was most likely 
the dimer o f c-Jun and c-Fos. Moreover, the large complex was also the primary 
complex o f which the formation was affected by androgens and EGF.
3. The Interaction between Androgen Receptors and AP-1
The AP-1 binding of AP-1 at the three PSMA sites was decreased by androgen and 
increased by EGF. In order to explain this result along with the observation that the 
transcription of PSMA was upregulated in the absence of androgen and downregulated 
by androgen, a model was proposed and shown in Fig. 36. According to this model, in 
the absence o f androgens. A P-1 proteins, free from the interaction with AR. are able to 
bind to the AP-1 sites and induce a high level o f PSMA transcription. This induction 
was further enhanced by EGF and TPA. the inducers o f AP-1. On the other hand, in 
the presence o f androgens, AR is activated and by interacting with AP-1, AR can exert 
the inhibitory effect on the AP-1 DNA binding activity to the PSMA promoter or the 
transactivation of the PSMA gene. Either o f these effects can result in the suppression 
o f PSMA transcription. Besides gaining support from the data in the present study, 
this model was also in agreement with the previous observation that the interaction 
between AR and AP-l can mutually suppress their DNA binding and transactivation
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activities (56,57). Since the interaction between AR and AP-1 has been demonstrated 
by coimmunoprecipitation (56,91), similar coimmunoprecipitation experiments were 
not repeated in this study. In stead, the focus o f this study was to examine specifically 
the presence o f AR in the AP-1 complexes at the three PSMA sites. The EMSA 
competition experiments with the ARE probe and AR specific antibody indicated that 
AR is indeed present in the AP-1 complexes at the three AP-1 sites. Furthermore, the 
competition by ARE was only seen in the nuclear extracts from LNCaP cells, but not 
in the nuclear extracts from PC-3 cells. Since PC-3 is a cell line that does not express 
AR, the results confirmed that the competition was specific to the AR expressing cell 
line LNCaP. All these results provided a clue to the interaction between AR and AP-1 
at A P-1 sites in the PSMA promoter.
Androgens are the most important steroid hormone in male reproductive organ 
development (92,93). Androgens were also related to the development o f prostate 
cancer. The effect o f androgens is mediated by AR. AR belongs to the nuclear 
receptor superfamily which includes receptors for steroids (such as estrogen, 
progesterone, glucocorticoid and mineralocorticoid), retinoid, thyroid hormone and 
Vitamin D. Before its association with androgens, the unliganded AR is associated 
with heat-shock proteins (HSPs) and is inactivated. Upon binding to androgens, the 
AR dissociates from the HSPs, forms homodimer and binds to specific DNA elements 
called androgen responsive elements (AREs) in the target gene promoter or enhancer 
region. The formation of AR/ARE complexes and the subsequent recruitment o f other 
cofactors result in the positive or negative regulation o f the target gene (94-97). Beside 
the direct involvement in the gene regulation, ARs can also regulate gene expression
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in an indirect format (98). In most cases, the indirect effects o f  androgens/AR are 
mediated by other transcription factors such AP-1 family members. Crosstalk between 
the AR and AP-1 may be the mechanism contributed to the inhibition o f the PSMA 
transcription by androgens. The interaction o f AR and AP-1 (c-Jun/c-Fos) has been 
related to both the inhibitory and stimulatory effects o f androgens. These interactions 
probably involved the DNA-binding domain and the hinge region o f the AR and the 
leucine zipper region o f c-Jun. The ultimate impact o f  the interaction on gene 
regulation may depend not only on the genomic structure o f  the target gene studied but 
also on the experimental conditions. The stimulatory effects o f c-Jun have been 
reported, which acts as a coactivator for the AR and mediates AR-induced 
transactivation (91). On the other hand, inhibitory effects have also been described in 
the regulation o f PSA gene where the interactions o f c-Jun and AR mutually inhibit 
binding to their respective responsive element (56). Following the same line, a similar 
inhibitory effect was proposed in this study for the androgenic regulation o f the PSMA 
gene. The results from this study suggested that the interaction between AR and AP-1 
may prevent AP-1 from binding to the respective sites in the PSMA promoter and 
therefore lead to the inhibition o f the PSMA transcription. Although the present study 
was conducted in LNCaP cells - an in vitro system, the in vivo observation o f the 
induction o f PSMA expression in the absence of androgens apparently has confirmed 
the proposed model in this study (19,22-24).
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D. CONCLUSIONS
•  • •
The two aims o f this study were 1) to quantitate serum PSMA using ProteinChip 
SELDI immunoassay; and 2) to characterize the transcriptional regulation o f PSMA 
gene by AP-1. Both o f these aims were successfully achieved in the study.
To accomplish the first aim, the baculovirus/insect cell system was used to express 
and purify a rPSMA. A recombinant baculovirus containing a 6x histidine-tagged 
PSMA gene was generated, from which rPSMA was expressed and purified using 
cobalt-chelating affinity chromatography. The purity and correct molecular size o f 
rPSMA were demonstrated by gel electrophoresis and mass spectrometry. Glycosidase 
digestion showed that the oligosaccharides on rPSMA are primarily N-linked high- 
mannose type. Although the glycosylation of rPSMA is different from the native 
PSMA, it did not affect the immunoreactivity o f rPSMA to antibodies specific for 
either the intra- or the extracellular domains of PSMA. The purified rPSMA was 
successfully used to develop a SELDI ProteinChip® immunoassay for quantitation of 
PSMA in serum. PSMA was captured from serum by anti-PSMA antibody bound to 
the ProteinChip arrays. The captured PSMA was detected by mass spectrometry and 
quantitated by comparing the mass signal integrals to a standard curve established 
using purified rPSMA. The levels o f serum PSMA from prostate cancer patients was 
significantly different from the levels in sera from patients with benign prostate 
hyperplasia, making it possible to discriminate BPH from PCA. especially in the PSA 
4-10ng/ml “grey zone”. This is, to the best of our knowledge, the first successful study
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to quantitate PSMA in serum and to demonstrate the potential o f PSMA as a clinically 
useful diagnostic biomarker for improving the specificity in differentiating prostate 
cancer from BPH. These results warrant further studies to evaluate the clinical utility 
o f the PSMA SELDI immunoassay.
For the second aim, sequence analysis predicted 14 putative AP-1 family 
transcription factors (c-Jun/c-Fos) binding sites in the upstream region and the first 
intron of the PSMA gene. The effect of EGF and TPA (both inducers o f the AP-1 
family transcription factors) on PSMA RNA levels was examined by Northern blot 
analyses. The two inducers were found to increase the PSMA RNA levels. However, 
in the presence o f androgens this induction was inhibited. The PSMA 
promoter/enhancer activity was analyzed by the luciferase reporter assay. A 0.8kb and 
2kb fragment upstream o f the PSMA coding region and the first intron were cloned 
into a pGL2 luciferase reporter vector, and the constructs designated PI, P2 and I/Pl 
respectively. The effect o f  androgens and EGF on the promoter/enhancer activity was 
examined by transfecting the reporter constructs individually into LNCaP cells, which 
express endogenous PSMA. The promoter activity o f PI. P2 and I/Pl fragments was 
shown to increase in the absence of androgens, with the highest activity found with the 
PI construct. In agreement with the Northern blot data, EGF induced the PSMA 
promoter/enhancer activity while androgens acted antagonistically on the EGF 
induction. The cotransfection o f the AP-1 expression vectors (pcDNA-cJun/cFos) with 
PI increased the luciferase activity, indicating the direct involvement o f AP-1 in the 
PSMA promoter activation. Electrophoretic mobility shift assays (EMSA) 
demonstrated the binding of AP-1 to the three AP-1 sites in PI, which are in the close
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vicinity o f the transcription initiation site. The specificity o f  this binding was 
confirmed by 1) the competition o f the unlabelled consensus AP-1 and AP-1 like 
binding sites; 2) the inhibition by the cJun and cFos specific antibodies; and 3) the 
binding o f in vitro translated AP-1 (cJun/cFos) proteins. Furthermore, the binding of 
AP-1 was reduced in the presence o f androgens and increased significantly by EGF. 
Additionally, the AP-1 binding was competed by either the unlabelled androgen 
response element (ARE) or the androgen receptor (AR) specific antibody, indicating 
that the AP-1 binding to the PSMA promoter might be inhibited by the interaction 
between androgen receptors and AP-1.
Overall the results suggest the direct involvement o f AP-1 (cJun/cFos) in the 
transcriptional activation o f the PSMA gene and the antagonistic effect o f androgen on 
the AP-1 induced PSMA promoter activity. We propose the following model to 
explain the regulation of the PSMA gene: in the presence o f androgens, the binding of 
AP-1 to the PSMA promoter is decreased, possibly by the interaction between AP-1 
and androgen receptors, resulting in the suppression of PSMA transcription; whereas 
in the absence of androgen, the binding of AP-1 to the PSMA promoter is increased, 
leading to the upregulation o f PSMA gene transcription. In summary, the study in the 
second aim demonstrates for the first time, that AP-1 family members are involved in 
the upregulation of the PSMA gene transcription in the absence o f androgen.
In conclusion, by developing a clinically useful SELDI immunoassay for 
quantitation of serum PSMA and characterizing the molecular mechanism underlying 
the transcriptional regulation o f the PSMA gene, the results from this study will
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facilitate both the basic understanding and the clinical utility o f PSMA in prostate 
cancer diagnosis and treatment.
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